



## Motor complications in an incident Parkinson's disease cohort

Journal:	<i>European Journal of Neurology</i>
Manuscript ID:	EJoN-15-0093.R1
Wiley - Manuscript type:	Original Papers
Date Submitted by the Author:	n/a
Complete List of Authors:	Scott, Nicholas; University of Aberdeen, Division of Applied Health Sciences Macleod, Angus; University of Aberdeen, Division of Applied Health Sciences Counsell, Carl; University of Aberdeen, Division of Applied Health Sciences;
Keywords:	Parkinson's disease < Movement disorders < NEUROLOGICAL DISORDERS

## Motor complications in an incident Parkinson's disease cohort

Nicholas W Scott<sup>1</sup>, Angus D Macleod<sup>1</sup>, Carl E Counsell<sup>1</sup>

---

**Address:** <sup>1</sup>Division of Applied Health Sciences  
University of Aberdeen  
Polwarth Building  
Foresterhill  
Aberdeen  
AB25 2ZD  
UK

**Corresponding author:** Dr. Angus D Macleod  
Tel +44(0)1224437120  
Fax +44(0)1224437285  
email: [angus.macleod@abdn.ac.uk](mailto:angus.macleod@abdn.ac.uk)

**Keywords:** Parkinson's disease  
Motor fluctuations  
Dyskinesias  
Motor complications  
Levodopa

**Abstract word count:** 249  
**Article word count:** 3412

**Running title:** Motor complications in PD

**Conflicts of Interest:** We declare we have no conflicts of interest.

**ABSTRACT****Background**

Levodopa treatment in Parkinson's disease (PD) causes motor fluctuations and dyskinesias, but few data describe their development or severity in unselected incident cohorts.

**Methods**

We gathered demographic, clinical, treatment, smoking, caffeine, and alcohol data from 183 people with PD from the PINE study, a community-based, incident cohort. With Kaplan-Meier survival analysis and Cox regression modelling we assessed the development, and severity, of dyskinesias and motor fluctuations and which factors independently influenced their onset.

**Results**

After mean follow-up of 59 months, 39 patients (21.3%) developed motor fluctuations and 52 (28.4%) developed dyskinesias. Kaplan-Meier estimates of the probability of motor fluctuations and dyskinesias after 5 years of dopaminergic treatment were 29.2% (95% confidence interval [CI] 21.5–38.8%) and 37.0% (95% CI 28.5–47.1%) respectively. 19.8% developed motor fluctuations requiring treatment changes but only 4.0% (95% CI 1.5–10.4%) developed dyskinesias requiring treatment changes by five years. Cumulative levodopa dose (Hazard ratio [HR] 1.38 [95% CI 1.19–1.60]), female sex (HR 2.41 [1.19–4.89]), and younger age at diagnosis (HR 1.08 [1.04–1.11]) were independently associated with development of motor fluctuations. Cumulative levodopa dose (HR 1.23 [1.08–1.40]), female sex (HR 2.51 [1.40–4.51]) were independently associated with dyskinesias. In exploratory analyses, moderate caffeine exposure was associated with fewer motor fluctuations, longer symptom duration with more dyskinesias, and tremor at diagnosis with higher rates of both complications.

**Conclusions**

In this community-based incident PD cohort, severe dyskinesias were rare. Cumulative levodopa dose was the strongest predictor of both dyskinesias and motor fluctuations.

## INTRODUCTION

Treatment of Parkinson's disease (PD), especially with levodopa, causes dyskinesias and motor fluctuations. These motor complications are potentially disabling and may adversely affect patients' quality of life.<sup>1-3</sup> A previous review of studies of motor complications estimated that the risk of developing motor fluctuations and dyskinesias were both about 40% after levodopa treatment for 4-6 years.<sup>4</sup> However, most previous studies have been based on unrepresentative samples, with attendant selection biases, such as cohorts from specialist clinics or clinical trials in which younger patients with fewer co-morbidities than the general PD population are often over-represented.<sup>5,6</sup> Only two representative, community-based incidence studies have examined the development of motor complications over time, both of which were small, only reported dyskinesias<sup>7,8</sup> and one was retrospective.<sup>8</sup>

Several risk factors for the development of dyskinesias have been identified, including: younger age at diagnosis, female sex, higher levodopa dose, longer duration of levodopa therapy, and lower body weight,<sup>8-14</sup> but most data come from non-incident or hospital-based studies. By contrast, few predictors of motor fluctuations have been identified but dose and duration on levodopa therapy are most commonly reported.<sup>12,15-18</sup> In addition, nicotine, caffeine and alcohol may protect against the development of PD<sup>19</sup> and there is some inconsistent clinical trial data to suggest caffeine and another adenosine A2A antagonist, may reduce dyskinesia risk.<sup>20,21</sup>

We therefore aimed to (i) describe the development of dyskinesias and motor fluctuations in a prospective, community-based, incident cohort of PD; (ii) assess what factors influence their development; and (iii) describe the development of severe motor complications.

## METHODS

### Study Design and Participants

We used data from the Parkinsonism Incidence in North-East Scotland (PINE) study, a community-based incidence study of PD and other parkinsonian disorders in Aberdeen and surrounding areas with prospective long-term follow-up.<sup>22,23</sup> Attempts were made to identify all newly diagnosed patients with degenerative or vascular parkinsonism between 2002 and 2004 (pilot phase) and 2006 to 2009 (main study phase) using multiple, overlapping methods for case ascertainment.<sup>23</sup> All patients were asked to consent to long-term annual follow-up with interim appointments as required for clinical management. The study was approved by the Multi-centre Research Ethics Committee for Scotland and conducted with the informed consent of the patients involved.

This analysis was restricted to patients who had a diagnosis of idiopathic PD at death or latest follow-up, made by a consultant neurologist with an interest in movement disorders (CEC) using the UK Brain Bank criteria,<sup>24</sup> insofar as follow-up duration permitted supportive criteria to be applied. 15% of patients with a latest diagnosis of PD had initially had an alternative diagnosis. Patients were excluded if they were not followed-up after baseline or if they had not received dopaminergic treatment. Patients were treated according to the clinical judgement of the treating clinicians.

### Data collection and assessment of motor complications

At the baseline (i.e. diagnostic) assessment and at subsequent follow-up appointments, consenting patients were interviewed and examined, and information gathered included patient demographics and clinical characteristics (including the Unified PD Rating Scale [UPDRS]) and details of parkinsonian medication. Data were also gathered on exposure to caffeine, alcohol and smoking at verbal interview, including age at first exposure, average level of exposure before baseline and, if relevant, year exposure stopped. At each annual assessment, patients were asked about their ongoing exposures.

1  
2  
3  
4  
5 Data on motor complications were gathered from the prospectively acquired records of the  
6  
7 examining study physician and from part IV of the UPDRS. In patients who reported motor  
8  
9 complications, the month and year of onset were recorded from patient self-report or, in the case of  
10  
11 asymptomatic dyskinesias that were seen at the assessment, the date of that assessment.  
12  
13 Dyskinesias did not have to be witnessed by a physician to be included, but if they were not seen  
14  
15 and the history was doubtful, they were not included. Severe motor complications were defined as  
16  
17 those which required changes to parkinsonian treatment after discussion with the patient about  
18  
19 their impact.  
20  
21  
22  
23

#### 24 **Analysis**

25  
26 The data were extracted from the PINE database (26<sup>th</sup> June, 2013), checked and cleaned. The  
27  
28 cumulative levodopa only dose and the total levodopa-equivalent dose (LED)<sup>25</sup> (including any  
29  
30 dopamine replacement therapy) were calculated up to four years from diagnosis since almost all  
31  
32 surviving patients had been followed-up for four years. Levodopa and levodopa-equivalent doses  
33  
34 were calculated as levodopa or levodopa-equivalent dose in milligrams multiplied by number of days  
35  
36 of treatment and divided by 10<sup>5</sup> to give units equivalent to about 70mg levodopa, on average, a day  
37  
38 for 4 years. Cumulative alcohol and caffeine lifetime exposure were divided into tertiles and smoking  
39  
40 exposure was categorised as never, low and high because there were large numbers of non-smokers  
41  
42 in our cohort. Cups of tea and coffee were assumed to contain 47mg and 62mg of caffeine  
43  
44 respectively.<sup>26</sup> Tertiles of cumulative alcohol and caffeine exposure over three years after diagnosis  
45  
46 were also calculated to investigate whether ongoing exposure after diagnosis was associated with  
47  
48 fewer motor complications.  
49  
50  
51  
52  
53  
54

55 We performed Kaplan-Meier survival analysis of motor fluctuation-free and dyskinesia-free survival  
56  
57 from the start of any dopamine replacement therapy (levodopa, dopamine agonist, MAO-B inhibitor)  
58  
59  
60

1  
2  
3 with patients censored at death or last follow-up. Survival analyses were also performed with  
4  
5 different time baselines to facilitate comparisons with previous studies: i) levodopa initiation; and ii)  
6  
7 diagnosis. Cox proportional hazards modelling was performed to assess what factors independently  
8  
9 influenced the development of motor complications (using start of dopaminergic treatment as the  
10  
11 baseline for survival). Univariable (unadjusted) hazards ratios were firstly calculated for all the  
12  
13 variables listed in table 1. There were too many variables to include all in a multivariable model. On  
14  
15 the basis of *a priori* evidence we selected four variables to include (irrespective of statistical  
16  
17 significance) in the two main Cox regression models (i.e. one predicting motor fluctuations and one  
18  
19 dyskinesias): age at diagnosis, sex, motor UPDRS score at baseline and cumulative levodopa dose up  
20  
21 to four years from diagnosis. This ensured no fewer than about 10 events per variable in the main  
22  
23 models.<sup>27</sup> Additional exploratory analyses were performed to investigate the role of other variables  
24  
25 including symptom duration prior to diagnosis, weight, MMSE score at diagnosis, different treatment  
26  
27 measures (cumulative levodopa-equivalent dose, starting levodopa within one year of diagnosis) and  
28  
29 measures of smoking, alcohol and caffeine exposure. These secondary analyses were performed by  
30  
31 creating models with the four pre-specified variables together with each of the additional variables  
32  
33 in turn. There were no missing data in the variables used in the main analysis; in the secondary  
34  
35 analysis, if missing data were present for a particular variable, these observations were excluded  
36  
37 from analyses including that variable. Statistical analyses were performed using SPSS version 21 and  
38  
39 Stata version 12.  
40  
41  
42  
43  
44  
45  
46  
47

## 48 RESULTS

49  
50 206 patients with a diagnosis of idiopathic PD at latest follow-up were identified from the PINE  
51  
52 database (Figure 1), of which seven declined clinical follow-up, ten died before their first follow-up  
53  
54 and six had not received dopaminergic medication by time of data extraction. These patients (mean  
55  
56 age 70.8) were not treated because they had mild disease with tremor dominance (N=3), had early  
57  
58  
59  
60

dementia while motor symptoms were still mild (N=1), refused treatment (N=1), or did not tolerate levodopa (N=1). The remaining 183 treated idiopathic PD patients (57.4% male, mean age at diagnosis 71.7 years) were included in the main analyses. The mean duration of follow-up was 59 months (SD 22). 66 patients (36.1%) died during the follow-up. Five patients (2.7%) were lost to clinical follow-up. 128 patients (69.9%) started levodopa within the first year of follow up (median duration to treatment onset 4 months, IQR 0-14 months). Most patients (69.9%) received levodopa in the first year after diagnosis and a further 24 (13.1%) received levodopa within four years of follow-up. The patients who received dopaminergic therapy in the first four years, but not levodopa, were mostly treated with ropinirole (33 patients), pramipexole (17 patients), selegiline (13 patients), COMT inhibitors (2 patients), rasagiline (1 patient), or ergot-derived dopamine agonists (2 patients).

### Motor Fluctuations

Motor fluctuations occurred in 39 patients (21.3%) (see table 1 and figure 2A). The majority of these were severe enough to require changes in therapy (25 patients [13.7% of total participants, 64.1% of those with motor fluctuations]). These changes were mostly increased frequency of levodopa dosage or adding controlled release levodopa at night. Kaplan-Meier estimates of probability of developing motor fluctuations at five years, with different baselines for time measurement, are shown in table 3. The factors independently associated with the development of motor fluctuations in the main multivariable model were higher cumulative levodopa dose, female sex, and younger age at diagnosis (Table 1). In secondary analyses the presence of tremor at diagnosis was associated with a higher rate and moderate (though not high) lifetime caffeine intake was associated with a lower rate of motor fluctuations.

**Table 1.** Characteristics of patients who developed motor fluctuations

Characteristics	Patients with fluctuations	Patients without	Unadjusted HR (95% CI)	Adjusted HR* (95% CI)
-----------------	----------------------------	------------------	------------------------	-----------------------



	N=39	fluctuations N=144		
Age at diagnosis in years, median (IQR)	71 (64-74)	74 (69-80)	0.97 (0.94-0.99)	0.93 (0.90-0.97)
Sex: Female, N (%)	23 (59.0%)	55 (38.2%)	1.80 (0.95-3.40)	2.41 (1.19-4.89)
Weight at diagnosis in kg, median (IQR)	70 (64-84)	73 (62-83)	1.00 (0.98-1.03)	1.02 (0.99-1.05)
Motor UPDRS at diagnosis, median (IQR)	26 (18-36)	24 (15-32)	1.02 (0.99-1.05)	1.00 (0.96-1.03)
MMSE at diagnosis, median (IQR) (N=14 missing)	29 (28-30)	29 (27-29)	1.17 (0.97-1.42)	1.13 (0.90-1.42)
Tremor at diagnosis, N (%)	37 (95.0%)	123 (85.4%)	3.50 (0.84-14.58)	4.80 (1.12-20.72)
Duration between symptom onset and diagnosis in years, median (IQR)	1.17 (0.83–2.00)	1.17 (0.75-2.06)	0.93 (0.75-1.14)	0.89 (0.71-1.13)
Started on Levodopa within 1 year from diagnosis, N (%)	25 (64.1%)	103 (71.5%)	0.91 (0.47-1.76)	0.75 (0.29-1.92)
Cumulative Levodopa dose 4 years from diagnosis, median (IQR)	5.56 (1.40-7.60)	2.56 (0.63-4.38)	1.16 (1.04-1.30)	1.38 (1.19-1.60)
Cumulative LED 4 years from diagnosis, median (IQR)	6.43 (3.37-7.60)	3.28 (1.88-5.08)	1.24 (1.08-1.46)	1.01 (0.76-1.36)
PD Subtype, N (%)				
PIGD	17 (43.6%)	75 (52.1%)	1	1
Intermediate	6 (15.4%)	20 (13.9%)	1.33 (0.53-3.38)	2.00 (0.73-5.44)
Tremor dominant	16 (41.0%)	49 (34.0%)	1.31 (0.66-2.60)	1.59 (0.78-3.28)
Smoking lifetime exposure, N (%)				
Pack years [cigarettes per day / 20 x number of years of exposure]				
Never	27 (69.2%)	78 (54.2%)	1	1
Low (1-18)	6 (15.4%)	37 (47.4%)	0.59 (0.24-1.43)	0.79 (0.32-1.94)
High (>18)	6 (15.4%)	29 (20.1%)	0.65 (0.27-1.57)	0.74 (0.30-1.85)
Current smokers at diagnosis, N (%)	4 (10.3%)	8 (5.5%)	1.70 (0.60-4.78)	1.40 (0.50-4.00)
Alcohol lifetime exposure, N (%)				
[units of alcohol per week x years of exposure]				
Never/Low(<40)	16 (41.0%)	45 (31.3%)	1	1
Moderate(40-240)	12 (30.8%)	49 (34.0%)	0.73 (0.35-1.56)	0.79 (0.35-1.77)
High(>240)	11 (28.2%)	50 (34.7%)	0.63 (0.29-1.36)	0.71 (0.30-1.70)
Alcohol 3 years after diagnosis, N (%)				
Never/Low(<1)	14 (35.9%)	58 (40.3%)	1	1
Moderate(1-11)	11 (28.2%)	38 (26.4%)	1.19 (0.54-2.62)	1.70 (0.73-3.97)
High(>11)	14 (35.9%)	48 (33.3%)	1.18 (0.56-2.47)	1.70 (0.79-3.60)
Caffeine lifetime exposure, N (%)				
[weight (in mg) per day x years of exposure]				
Never/Low(< 10,600)	17 (43.6%)	44 (30.6%)	1	1
Moderate (10,600 - 16,400)	13 (33.3%)	48 (33.3%)	0.53 (0.26-1.10)	0.34 (0.15-0.76)
High (>16,400)	9 (23.1%)	52 (36.1%)	0.50 (0.22-1.12)	0.57 (0.24-1.40)
Caffeine 3 years after diagnosis, N (%)				
Never/Low (<513)	8 (20.5%)	53 (36.8%)	1	1
Moderate(513-744)	18 (46.2%)	42 (29.2%)	1.59 (0.68-3.72)	1.58 (0.62-4.06)
High(>744)	13 (33.3%)	49 (34.0%)	1.10 (0.46-2.67)	1.12 (0.44-2.89)

\*Variables adjusted for the variables in the final multivariable model (age at diagnosis, sex, motor UPDRS at diagnosis, and cumulative levodopa dose 4). Abbreviation: PIGD= postural instability and gait disorder.

### Dyskinesias

52 patients (28.4%) developed dyskinesias (see table 2 and figure 2B). At onset, only three patients (1.6% of total participants, 5.8% of those with dyskinesia) rated their dyskinesias as painful and five

(2.7% of total participants, 9.6% of those with dyskinesia) as mildly disabling; the rest were not disabling. Only 8 patients (4.4% of total participants, 15.4% of those with dyskinesia) developed dyskinesias which required treatment changes (such as decrease of levodopa dose or addition of amantadine). The median dyskinesia-free survival time was 85 months. Kaplan-Meier estimates of the probability of developing dyskinesias after five years, with different baselines for time measurement, are shown in table 3. Higher cumulative levodopa dose and female sex were found to be independent risk factors for the development of dyskinesias in the main model (Table 2). In the additional models, symptom duration and the presence of tremor at diagnosis were associated with more dyskinesias and there was a suggestion that higher MMSE score was associated with increased risk.

**Table 2.** Characteristics of patients who developed dyskinesias

Characteristics	Patients with dyskinesias N=52	Patients without dyskinesias N=131	Unadjusted HR (95% CI)	Adjusted HR* (95% CI)
Age at diagnosis in years, median (IQR)	73 (70-78)	73 (65-80)	1.02 (0.99-1.05)	1.00 (0.97-1.03)
Sex: Female, N (%)	29 (55.8%)	49 (37.4%)	1.79 (1.03-3.10)	2.51 (1.40-4.51)
Weight at diagnosis in Kg, median (IQR)	67 (60-75)	75 (64-85)	0.97 (0.96-0.99)	0.99 (0.96-1.01)
Motor UPDRS at diagnosis, median (IQR)	29 (19-37)	23 (15-32)	1.03 (1.01-1.06)	1.01 (0.98-1.04)
MMSE at diagnosis, median (IQR) (N=14 missing)	29 (28-29)	29 (27-29)	1.07 (0.94-1.23)	1.17 (1.00-1.36)
Tremor at diagnosis, N (%)	49 (94.2%)	111 (84.7%)	2.82 (0.88-9.07)	3.68 (1.14-11.90)
Duration between symptom onset and diagnosis in years, median (IQR)	1.21 (0.71-2.15)	1.08 (0.75-2.00)	1.19 (1.05-1.35)	1.02 (1.01-1.03)
Started on Levodopa within 1 year from diagnosis, N (%)	41 (78.8%)	87 (66.4%)	2.20 (1.13-4.30)	1.55 (0.65-3.70)
Cumulative Levodopa dose 4 years from diagnosis, median (IQR)	4.48 (2.34-6.90)	2.37 (0.23-4.07)	1.19 (1.08-1.32)	1.23 (1.08-1.40)
Cumulative LED 4 years from diagnosis, median (IQR)	5.87 (3.06-7.10)	3.28 (1.73-4.99)	1.19 (1.06-1.35)	1.00 (0.75-1.30)
PD Subtype, N (%)				
PIGD	26 (50.0%)	66 (50.4%)	1	1
Intermediate	6 (11.5%)	20 (15.3%)	0.76 (0.31-1.85)	1.23 (0.50-3.10)
Tremor dominant	20 (38.5%)	45 (34.3%)	0.96 (0.54-1.73)	1.64 (0.86-3.12)
Smoking lifetime exposure, N (%)				
Pack years [cigarettes per day / 20 x number of years of exposure]				
Never	30 (57.7%)	75 (57.3%)	1	1
Low (1-18)	10 (19.2%)	33 (25.2%)	0.95 (0.46-1.95)	1.08 (0.52-2.23)
High (>18)	12 (23.1%)	23 (17.6%)	1.40 (0.71-2.73)	1.21 (0.60-2.44)
Current smokers at diagnosis, N (%)	4 (8.0%)	8 (6.1%)	0.85 (0.30-2.37)	0.80 (0.30-2.30)
Alcohol lifetime exposure, N (%)				

[units of alcohol per week x years of exposure]	Never/Low(<40)	22 (42.3%)	39 (29.8%)	1	1
	Moderate(40-240)	14 (26.9%)	47 (35.9%)	0.53 (0.27-1.04)	0.63 (0.31-1.30)
	High(>240)	16 (30.8%)	45 (34.4%)	0.66 (0.35-1.30)	0.80 (0.38-1.68)
Alcohol 3 years after diagnosis, N (%)					
	Never/Low(<1)	21 (40.4%)	51 (38.9%)	1	1
	Moderate(1-11)	11 (21.2%)	38 (29.0%)	0.67 (0.32-1.39)	0.90 (0.42-1.92)
	High(>11)	20 (38.5%)	42 (32.1%)	1.09 (0.59-2.01)	1.63 (0.85-3.14)
Caffeine lifetime exposure, N (%)					
[weight (in mg) per day x years of exposure]	Never/Low(< 10,600)	16 (30.7%)	45 (34.4%)	1	1
	Moderate (10,600 - 16,400)	20 (38.5%)	41 (31.3%)	1.26 (0.65-2.43)	0.81 (0.40-1.64)
	High (>16,400)	16 (30.7%)	45 (34.4%)	1.13 (0.56-2.25)	0.80 (0.38-1.67)
Caffeine 3 years after diagnosis, N (%)					
	Never/Low (<513)	11 (21.2%)	50 (38.2%)	1	1
	Moderate(513-744)	20 (38.5%)	40 (30.5%)	1.56 (0.74-3.29)	1.40 (0.64-3.08)
	High(>744)	21 (40.4%)	41 (31.3%)	1.56 (0.75-3.24)	1.37 (0.65-2.87)

\*Variables are adjusted for the variables in the final multivariable model (age at diagnosis, sex, motor UPDRS at diagnosis, and cumulative levodopa dose). Abbreviation: PIGD= postural instability and gait disorder.

**Table 3:** Kaplan-Meier probabilities of developing motor fluctuations and dyskinesias after five years from dopaminergic treatment initiation, from levodopa initiation, and from diagnosis.

Baseline for time measurement	Motor fluctuations	Dyskinesias
Any complication		
Starting dopaminergic treatment (N=183)	29.2% (21.5–38.8)	37.0% (28.5–47.1)
Starting levodopa treatment (N=160)	30.6% (22.6–40.7)	43.6% (33.7–54.9)
Diagnosis (N=189)	22.8% (16.7–30.7)	29.6% (22.7–37.8)
Severe complications		
Starting dopaminergic treatment (N=183)	19.8% (13.4–28.8)	4.0% (1.5–10.4)

95% confidence intervals are in parentheses.

### Motor fluctuations and dyskinesias

23 patients (12.6%) developed both fluctuations and dyskinesias, of whom 14 had developed dyskinesias first.

## DISCUSSION

1  
2  
3 About 30% of patients with PD developed motor fluctuations and about 37% developed dyskinesias  
4  
5 within five years of starting dopaminergic treatment. These were higher risks than described in two  
6  
7 other community-based incidence cohorts that examined the development of dyskinesias. A Mayo  
8  
9 Clinic series reported that 30% of patients developed dyskinesias by five years of starting levodopa<sup>8</sup>  
10  
11 and in another study fewer than 20% of patients developed dyskinesias five years from diagnosis.<sup>7</sup>  
12  
13 The reasons for these differences, between similar studies, are unclear. No previous community-  
14  
15 based inception studies have reported the frequency of motor fluctuations. We found complications  
16  
17 to be less common than several other studies, some of which were older and therefore used higher  
18  
19 levodopa doses than are used in current practice.<sup>4,18</sup> Dyskinesias were more common in our cohort  
20  
21 than motor fluctuations, similar to some studies<sup>15,28</sup> but not others.<sup>16,12,18</sup> Disabling dyskinesias were  
22  
23 rare and, although most patients with motor fluctuations did need changes in treatment, very few  
24  
25 (4%) developed dyskinesias necessitating treatment changes. This is lower than one previous  
26  
27 incident study in which 17% of patients required treatment changes for dyskinesias within five years  
28  
29 of levodopa initiation.<sup>8</sup> That study used patient records between 1976 and 1990 and the lower  
30  
31 incidence of severe dyskinesias in our study, could be due to lower levodopa doses used in more  
32  
33 recent prescribing practice.  
34  
35  
36  
37  
38  
39

40 Levodopa exposure has consistently been reported as the strongest risk factor for the development  
41  
42 of motor fluctuations and dyskinesias in observational studies,<sup>4,8,16</sup> randomised trials of levodopa  
43  
44 versus dopamine agonists<sup>29,30</sup> and randomised trials of different levodopa doses.<sup>31</sup> Previous studies  
45  
46 have investigated several measures of levodopa exposure, including the initial average daily dose;<sup>7</sup>  
47  
48 average daily LED;<sup>8</sup> or levodopa dose at onset of dyskinesias (or study end in those without  
49  
50 dyskinesias).<sup>12</sup> Here we have compared cumulative both levodopa only and levodopa-equivalent  
51  
52 doses up to four years and early (within one year of diagnosis) commencement of levodopa.  
53  
54 Although these variables were correlated, only cumulative levodopa dose was significantly  
55  
56 associated with motor complications when they were entered into a multivariable model together.  
57  
58  
59  
60

1  
2  
3 This suggests that there is little additional effect of non-levodopa dopaminergic treatments, similar  
4 to findings from a recent meta-analysis.<sup>32</sup> It also suggests there is no absolute requirement to avoid  
5 early levodopa treatment in PD but, as others have suggested,<sup>12</sup> it is important to use the smallest  
6 dose that adequately controls the patient's symptoms throughout the course of PD. The fact that  
7 baseline motor severity (UPDRS) was not an independent risk factor for motor complications  
8 suggests that the association between cumulative levodopa dose and motor complications is not just  
9 due to worse disease severity with greater dopaminergic neuronal loss in those needing more  
10 levodopa. This conflicts with one large trial which found that both baseline disease severity and  
11 levodopa doses were associated with higher frequency of motor complications.<sup>12</sup> However, evidence  
12 that levodopa increases risk of dyskinesias independently of disease severity also comes from  
13 randomised clinical trials, in which disease severity is randomly allocated to each arm, and those  
14 with higher doses of levodopa<sup>31</sup> or levodopa and entacapone<sup>33</sup> had higher incidence of dyskinesias.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 Many previous studies have shown that younger age at onset is associated with more dyskinesias,<sup>9,10</sup>  
32 and it was the most powerful predictor in a recent large trial.<sup>12</sup> We found that age at diagnosis did  
33 not predict dyskinesias, similar to another community-based incidence study.<sup>7</sup> It may be that, as a  
34 community-based incidence study, with proportionally few young-onset patients (4.4% under 50),  
35 there was insufficient power to detect an effect of age on dyskinesias.  
36  
37  
38  
39  
40  
41  
42  
43

44 Duration between symptom onset and diagnosis was found to be an independent risk factor for  
45 developing dyskinesias but not motor fluctuations. This result was independent of baseline disease  
46 severity and levodopa dose so does not appear to be an effect of those presenting later being  
47 treated with higher doses of levodopa. This finding must be interpreted cautiously because it was a  
48 secondary analysis and the variable is subject to recall bias but it may suggest that patients with  
49 more indolent onset of their PD symptoms may be at a higher risk of developing dyskinesias.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The presence of tremor at diagnosis was associated with higher risk of both motor fluctuations and  
4 dyskinesias in the secondary analyses, which contrasts with a previous smaller study.<sup>34</sup> Although  
5 consistent for both types of complications, the number without any tremor at baseline in this post-  
6 hoc analysis was small so this finding, whilst novel and interesting, requires replication.  
7  
8  
9

10  
11  
12  
13  
14 Female gender was an independent risk factor for both motor fluctuations and dyskinesias, as  
15 previous studies have also shown.<sup>12</sup> The reasons for gender differences in the development of motor  
16 complications are unclear. A possible explanation is that lower average weight in females results in  
17 higher levodopa doses per body weight, and some previous studies found lower weight was a risk  
18 factor for dyskinesias.<sup>35,36</sup> We did not, however, demonstrate an association with baseline weight  
19 but changes in weight after diagnosis may be more important in the development of complications.  
20  
21  
22 It has also been suggested that females have a reduced genetic protection from a dopamine  
23 receptor polymorphism,<sup>11</sup> and hormonal differences may be important, with evidence from animal  
24 models of effects of oestrogen on the basal ganglia.<sup>37</sup>  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 Moderate lifetime caffeine exposure was associated with a reduced risk of developing motor  
36 fluctuations in the secondary multivariable analyses but there was no dose-response gradient and,  
37 given the large number of associations tested in the secondary analyses, it may well be a false  
38 positive. Nevertheless, a clinical trial showed caffeine lowered risk of dyskinesias<sup>20</sup> and a trial of  
39 another adenosine A2A antagonist, istradefylline reduced daily OFF time.<sup>21</sup> We did not find smoking  
40 or alcohol exposure, either before or after diagnosis to be associated with lower risk of dyskinesias.  
41  
42  
43 This is consistent with a previous study which showed smoking was not associated with motor  
44 complications.<sup>14</sup> However, we lacked power to identify small effects of these exposures on motor  
45 complications.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The principal strengths of this study are its prospective design; the representative sample (attempts  
4 were made to identify all patients in the community with a new parkinsonian syndrome); regular  
5 reviewed of diagnoses to improve diagnostic accuracy; frequent (at least yearly) clinical review to  
6 obtain data on motor complications; very high study retention; and careful statistical analyses.  
7  
8 Additionally, cumulative levodopa doses were calculated up to 4 years rather than at complication  
9 onset. This is clearly better than comparing levodopa dose at onset of motor complications with  
10 levodopa dose at end of study in those without complications as this is confounded by difference in  
11 time.  
12  
13  
14  
15  
16  
17  
18  
19

20  
21  
22 The study has several limitations. Firstly, study size, while not small in terms of previous studies of  
23 motor complications, is insufficient to identify weak associations or investigate interactions.  
24  
25 Secondly, average follow-up duration was only about five years, so better data may be obtained with  
26 longer follow-up. Thirdly, some inaccuracy in defining onset of complications is inevitable. Exact  
27 timing of onset of both dyskinesias and motor fluctuations was mostly subject to patient recall,  
28 although some patients' dyskinesias were observed at clinic visits before they were noticed by the  
29 patients themselves, and were recorded as starting when seen. Thus the time to onset of dyskinesias  
30 may be overestimated. Assessment of severity was based on data about changes in therapy, which  
31 was derived from comprehensive clinical letter that invariably included reasons for treatment  
32 changes so we believe this was a reliable assessment. Fourthly, the secondary analyses must be  
33 considered as exploratory as many variables were examined and type I errors are possible. Fifthly,  
34 data on caffeine, smoking and alcohol were partly retrospective, only average exposures were used,  
35 and we did not gather data on sources of caffeine other than tea and coffee.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51  
52  
53 In conclusion, we are the first to describe the development of both motor fluctuations and  
54 dyskinesias in a representative, community-based, incident cohort of PD. We estimate that 29% and  
55 37% develop motor fluctuations and dyskinesias respectively after 5 years of dopaminergic  
56  
57  
58  
59  
60

1  
2  
3 treatment. Dyskinesias requiring treatment changes were rare (4% at 5 years), which is lower than  
4  
5 previous estimates. Higher cumulative levodopa dose, female sex, and tremor at diagnosis were  
6  
7 independent risk factors for both motor complications; moderate lifetime caffeine exposure and  
8  
9 younger age for fewer motor fluctuations; and longer pre-diagnosis symptom duration for more  
10  
11 dyskinesias. Further work with more patients with longer follow-up would be useful for more  
12  
13 detailed analysis of risk factors. Individual-patient-data meta-analysis of existing representative  
14  
15 studies would be an efficient way to do this.  
16  
17

## 20 **ACKNOWLEDGEMENTS**

21  
22  
23  
24 We acknowledge funding for the PINE study from Parkinson's UK, the Scottish Chief Scientist Office,  
25  
26 the BMA Doris Hillier award, RS Macdonald Trust, the BUPA Foundation, NHS Grampian  
27  
28 endowments and SPRING. We thank the patients for their participation and the research staff who  
29  
30 collected data and supported the study database.  
31  
32

## 35 **AUTHOR'S ROLES**

36  
37  
38  
39 The authors contributed to the following specific roles in the project and manuscript preparation as  
40  
41 indicated:  
42

- 43 1. Research project: A. Conception, B. Organization, C. Execution;
- 44 2. Statistical Analysis: A. Design, B. Execution, C. Review and Critique;
- 45 3. Manuscript Preparation: A. Writing of the first draft, B. Review and Critique

46  
47  
48  
49 Nicholas W Scott (1B, 1C, 2B, 2C, 3A)

50  
51  
52  
53 Angus D Macleod (1B, 2A, 2B, 2C, 3B)

54  
55  
56  
57  
58  
59  
60 Carl E Counsell (1A, 1B, 2C, 3B)



## FINANCIAL DISCLOSURE

Nicholas W Scott: none

Angus D Macleod: Funded by a Clinical Academic Fellowship from the Scottish Chief Scientist Office.

Also received research funding from Parkinson's UK.

Carl E Counsell: Research funding from Parkinson's UK, Scottish Chief Scientist Office, National Institute of Health Research, and Engineering and Physical Sciences Research Council

## REFERENCES

1. Samii A, Nutt JG, Ransom BR. Parkinson's disease. *Lancet* 2004; **363** (9423) :1783–1794.
2. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. *Movement Disorders* 2005; **20** (2): 224-230.
3. Marras C, Lang A, Krahn M, Tomlinson G, Naglie G. Parkinson Study Group, Quality of life in early Parkinson's disease. *Movement Disorders* 2004; **19** (1): 22-28.
4. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. *Movement Disorders* 2001; **16** (3): 448-458.
5. Rybicki BA, Johnson CC, Gorell JM. Demographic differences in referral rates to neurologists of patients with suspected Parkinson's disease: implications for case-control study design. *Neuroepidemiology* 1995; **14** (2): 72–81.
6. Fitzsimmons PR, Blayney S, Mina-Corkill S, Scott GO. Older participants are frequently excluded from Parkinson's disease research. *Parkinsonism Related Disorders* 2012; **18** (5): 585–589.

- 1  
2  
3 7. Evans JR, Mason SL, Williams-Gray CH, et al. The natural history of treated Parkinson's disease in  
4 an incident, community based cohort. *J Neurology Neurosurgery Psychiatry* 2011; **82** (10): 1112-  
5 1118.  
6
- 7  
8  
9 8. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk  
10 among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. *Archives*  
11 *Neurology* 2006; **63** (2): 205-209.  
12
- 13  
14  
15 9. Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of  
16 Parkinson's disease onset. *Movement Disorders* 2005; **20** (3): 342-434.  
17
- 18  
19  
20 10. Ku S, Glass GA. Age of Parkinson's disease onset as a predictor for the development of  
21 dyskinesia. *Movement Disorders* 2010; **25** (9): 1177-1182.  
22
- 23  
24  
25 11. Zappia M, Annesi G, Nicoletti G, et al. Sex Differences in clinical and genetic determinants of  
26 levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. *Archives Neurology*  
27 2005; **62** (4): 601-605.  
28
- 29  
30  
31 12. Olanow CW, Kieburtz K, Rascol O, et al. Factors Predictive of the Development of Levodopa-  
32 Induced Dyskinesia and Wearing-Off in Parkinson's Disease. *Movement Disorders* 2013; **28** (8):  
33 1064-1071.  
34
- 35  
36  
37 13. Rascol O, Brooks DJ, Korczyn AD, et al. Development of dyskinesias in a 5-year trial and ropinirole  
38 and L-dopa. *Movement Disorders* 2006; **21** (11): 1844-1850.  
39
- 40  
41  
42 14. Hassin-Baer S, Molchadski I, Cohen OS, et al. Gender effect on time to levodopa-induced  
43 dyskinesias. *Journal of Neurology* 2011; **258** (11): 2048-2053.  
44
- 45  
46  
47 15. Garcia-Ruiz PJ, del Val J, Fernandez IM, Herranz A. What factors influence motor complications in  
48 Parkinson disease?: A 10-year prospective study. *Clinical Neuropharmacology* 2012; **35** (1):1-5.  
49
- 50  
51  
52 16. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease: a community-  
53 based study. *Brain* 2000; **123** (11): 2297-2305.  
54
- 55  
56  
57 17. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations.  
58 *Movement Disorders* 2005; **20** (Suppl. 11): S11-16.  
59  
60

- 1  
2  
3 18. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor  
4  
5 fluctuations and dyskinesias in Parkinson disease. *Archives Neurology* 2006; **63** (12): 1756–1760.
- 6  
7 19. Noyce AJ, Bestwick JP, Silveira-Moriyama, et al. Meta-analysis of early nonmotor features and  
8  
9 risk factors for Parkinson disease. *Annals Neurology* 2012; **72** (6): 893-901.
- 10  
11 20. Wills AM, Eberly S, Tennis M, et al. Caffeine consumption and risk of dyskinesia in CALM-PD.  
12  
13 *Movement Disorders* 2013; **28** (3): 380-383.
- 14  
15 21. Mizuno Y, Kondo T, Japanese Istradefylline study group. Adenosine A2a receptor antagonist  
16  
17 Istradefylline reduces daily OFF time in Parkinson's disease. *Movement Disorders* 2013; **28** (8):  
18  
19 1138-1141.
- 20  
21 22. Taylor KS, Counsell CE, Harris CE, Gordon JC, Smith WC. Pilot study of the incidence and  
22  
23 prognosis of degenerative Parkinsonian disorders in Aberdeen, United Kingdom: methods and  
24  
25 preliminary results. *Movement Disorders* 2006; **21** (7): 976–982.
- 26  
27 23. Caslake R, Scott N, Gordon J, et al. Age-, gender-, and socioeconomic status-specific incidence of  
28  
29 Parkinson's disease and parkinsonism in North East Scotland: The PINE study. *Parkinsonism*  
30  
31 *Related Disorders* 2013; **19** (5): 515-521.
- 32  
33 24. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's  
34  
35 disease: a clinico-pathological study of 100 cases. *J Neurology Neurosurgery Psychiatry* 1992; **55**  
36  
37 (3): 181-184.
- 38  
39 25. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose  
40  
41 equivalency reporting in Parkinson's disease. *Movement Disorders* 2010; **25** (15): 2649-2653.
- 42  
43 26. U.S. Department of Agriculture, Agriculture Research Service. USDA National Nutrient Database  
44  
45 for Standard Reference, Release 24. 2011.
- 46  
47 27. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in  
48  
49 proportional hazards regression analysis, II: accuracy and precision of regression estimates.  
50  
51 *Journal of Clinical Epidemiology* 1995; **48** (12): 1503-1510.
- 52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 28. Mazzella L, Yahr MD, Marinelli L, Huang N, Moshier E, Di Rocco A. Dyskinesias predict the onset  
4 of motor response fluctuations in patients with Parkinson's disease on l-dopa monotherapy,  
5 *Parkinsonism Related Disorders* 2005; **11** (3): 151-155.  
6  
7  
8  
9  
10 29. Parkinson study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease. A  
11 randomised controlled trial. *JAMA* 2000; **284** (15): 1931-1938.  
12  
13  
14 30. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs  
15 levodopa in early Parkinson disease. *Archives Neurology* 2009; **66** (5): 563-570.  
16  
17  
18 31. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. *New*  
19 *England Journal of Medicine* 2004; **351** (24): 2498-2508.  
20  
21  
22 32. Chondrogiorgi M, Tatsioni A, Reichmann H and Konitsiotis S. Dopamine agonist monotherapy in  
23 Parkinson's disease and potential risk factors for dyskinesia: a meta-analysis of levodopa  
24 controlled trials. *European Journal of Neurology* 2014; **21** (3): 433-440.  
25  
26  
27  
28 33. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without  
29 entacapone in early Parkinson disease. The STRIDE-PD study. *Annals of Neurology* 2010; **68** (1):  
30 18-27.  
31  
32  
33  
34 34. Kipfer S, Stephan MA, Schüpbach WM, Ballinari P, Kaelin-Lang A. Resting tremor in Parkinson  
35 disease: a negative predictor of levodopa-induced dyskinesia. *Archives Neurology* 2011; **68** (8):  
36 1037-1039.  
37  
38  
39  
40 35. Sharma JC, Macnamara L, Hasoon M, Vassallo M, Ross IN. Cascade of levodopa dose and weight  
41 related dyskinesia in Parkinson's disease (LD-WD-PD cascade). *Parkinsonism Related Disorders*  
42 2006; **12** (8): 499-505.  
43  
44  
45  
46 36. Sharma JC, Ross IN, Rascol O, Brooks D. Relationship between weight, levodopa and dyskinesia:  
47 the significance of levodopa dose per kilogram body weight. *European Journal of Neurology*  
48 2008; **15** (5): 493-496.  
49  
50  
51  
52 37. Smith KM, Dahodwala, N. Sex differences in Parkinson's disease and other movement disorders.  
53 *Experimental Neurology* 2014; 259: 44-56.  
54  
55  
56  
57  
58  
59  
60

**FIGURE LEGENDS**

Figure 1. Flow chart of patients included in the analysis and initiation of levodopa treatment. FU: Follow-Up.

\*Patients received only dopamine agonist or MAO-B inhibitors within 4 years of follow-up, except for 5 patients who received treatment after 4 years of follow-up.

Figure 2. Kaplan-Meier estimates of the probability that PD patients on a dopaminergic therapy will be free from (A) motor fluctuations and (B) dyskinesias. In each graph, the blue line represents the development of any motor complication and the red represents the development of severe complications, i.e., those needing changes to treatment.

## Motor complications in an incident Parkinson's disease cohort

Nicholas W Scott<sup>1</sup>, Angus D Macleod<sup>1</sup>, Carl E Counsell<sup>1</sup>

---

**Address:** <sup>1</sup>Division of Applied Health Sciences  
University of Aberdeen  
Polwarth Building  
Foresterhill  
Aberdeen  
AB25 2ZD  
UK

**Corresponding author:** Dr. Angus D Macleod  
Tel +44(0)1224437120  
Fax +44(0)1224437285  
email: [angus.macleod@abdn.ac.uk](mailto:angus.macleod@abdn.ac.uk)

**Keywords:** Parkinson's disease  
Motor fluctuations  
Dyskinesias  
Motor complications  
Levodopa

**Abstract word count:** 249  
**Article word count:** 3412

**Running title:** Motor complications in PD

**Conflicts of Interest:** We declare we have no conflicts of interest.

## ABSTRACT

### Background

Levodopa treatment in Parkinson's disease (PD) causes motor fluctuations and dyskinesias, but few data describe their development or severity in unselected incident cohorts.

### Methods

We gathered ~~data on~~ demographics, clinical ~~details~~, ~~drug~~ treatment, ~~and~~ smoking, caffeine, and alcohol ~~data history~~ from 183 people with PD from the PINE study, a community-based, incident cohort. With Kaplan-Meier survival analysis and Cox regression modelling we assessed the development, and severity, of dyskinesias and motor fluctuations and which factors independently influenced their onset.

### Results

After mean follow-up of 59 months, 39 patients (21.3%) developed motor fluctuations and 52 (28.4%) developed dyskinesias ~~after mean 59 months (SD)~~. Kaplan-Meier estimates of the probability of motor fluctuations and dyskinesias after 5 years of dopaminergic treatment ~~was~~ were 29.2% (95% confidence interval [CI] 21.5–38.8%) and ~~of dyskinesias was~~ 37.0% (95% CI 28.5–47.1%) respectively. 19.8% developed motor fluctuations requiring treatment changes but only 4.0% (95% CI 1.5–10.4%) developed dyskinesias requiring treatment changes by five years. Cumulative levodopa dose (Hazard ratio [HR] 1.38 [95% CI 1.19–1.60]), female sex (HR 2.41 [1.19–4.89]), ~~and~~ and younger age at diagnosis (HR 1.08 [1.04–1.11]) – were independently associated with development of motor fluctuations. Cumulative levodopa dose (HR 1.23 [1.08–1.40]), ~~and~~ female sex (HR 2.51 [1.40–4.51]) were independently associated with dyskinesias. In ~~secondary~~ exploratory analyses, moderate caffeine exposure was associated with ~~lower rates of fewer~~ motor fluctuations, longer symptom duration with more dyskinesias, and tremor at diagnosis with higher rates of both complications.

### Conclusions

In this community-based incident PD cohort, severe dyskinesias were rare. Cumulative levodopa dose was the strongest predictor of both dyskinesias and motor fluctuations.

## INTRODUCTION

Treatment of Parkinson's disease (PD), especially with levodopa, ~~is associated with the development causes of motor complications, namely~~ dyskinesias and motor fluctuations. These ~~motor complications~~ are ~~common and~~ potentially disabling ~~consequences of chronic levodopa therapy~~ and may adversely affect patients' quality of life.<sup>1-3</sup>

~~Ahlskog and Muentzer reviewed~~ A previous ~~review of~~ studies of ~~dyskinesias and~~ motor ~~fluctuations complications~~ and estimated that the risk of developing motor fluctuations and dyskinesias were both about 40% after levodopa treatment for 4-6 years.<sup>4</sup> However, most previous studies have been based on unrepresentative samples, with attendant selection biases, such as cohorts ~~derived~~ from specialist clinics ~~cohorts or clinical trials~~ in which younger ~~onset~~ patients ~~with fewer co-morbidities than the general PD population~~ are often over-represented,<sup>5</sup> ~~or from clinical trials in which trial participants again tend to be~~ ~~are, on average, younger than the general PD population with fewer co-morbidities.~~<sup>6</sup> Only two representative, community-based incidence studies have examined the development of motor complications over time, both of which were small, only reported dyskinesias<sup>7,8</sup> and one was retrospective.<sup>8</sup> ~~The latter showed that whilst dyskinesias were common (30%) at five years, most were mild and only 17% required treatment adjustment.~~<sup>8</sup>

Several risk factors for the development of dyskinesias have been identified, including: younger age at ~~PD~~ diagnosis, female sex, higher levodopa dose, longer duration of levodopa therapy, and lower body weight.<sup>8-14</sup> ~~The two previous community based incident cohorts both found that higher initial levodopa dose was an independent risk factor for developing dyskinesias, whereas only one<sup>8</sup> found age at diagnosis to be an independent risk factor but most data come from non-incident or hospital-based studies.~~ By contrast, ~~relatively few data on~~ predictors of motor fluctuations ~~are available~~ ~~have been identified~~ but dose and duration on levodopa therapy are most commonly reported.<sup>12,15-18</sup> In



1  
2  
3 addition, ~~cigarette smoking~~nicotine, caffeine and alcohol may protect against the development of  
4 PD<sup>19</sup> and there is ~~also some inconsistent clinical trial data~~evidence from clinical trials to suggest that  
5  
6 caffeine and another adenosine A2A antagonist, may reduce ~~dyskinesia~~the risk of developing motor  
7  
8 complications.<sup>20,21</sup>  
9  
10  
11  
12

13  
14 We therefore aimed to (i) describe the development of dyskinesias and motor fluctuations in a  
15  
16 prospective, community-based, incident cohort of ~~treated~~PD; (ii) assess what factors influence their  
17  
18 development; and (iii) describe the development of severe ~~dyskinesias and~~ motor  
19  
20 ~~fluctuations~~complications.  
21  
22  
23  
24  
25  
26  
27  
28

## 29 METHODS

### 30 Study Design and Participants

31  
32 We used data from the Parkinsonism Incidence in North-East Scotland (PINE) study, a community-  
33  
34 based incidence study of PD and other parkinsonian~~ism~~ disorders in Aberdeen and surrounding areas  
35  
36 with prospective long-term follow-up.<sup>22,23</sup> Attempts were made to identify all newly diagnosed  
37  
38 patients with degenerative or vascular parkinsonism between 2002 and 2004 (pilot phase) and 2006  
39  
40 to 2009 (main study phase) using multiple, overlapping methods for case ascertainment.<sup>23</sup> All  
41  
42 patients were asked to consent to long-term annual follow-up with interim appointments as  
43  
44 required for clinical management. The ~~PINE~~ study was approved by the Multi-centre Research Ethics  
45  
46 Committee for Scotland and ~~was~~ conducted with the informed consent of the patients involved.  
47  
48  
49  
50  
51  
52

53  
54 This analysis was restricted to patients who had a diagnosis of idiopathic PD at death or latest  
55  
56 follow-up, made by a consultant neurologist with an interest in movement disorders (CEC) using the  
57  
58 UK Brain Bank criteria,<sup>24</sup> insofar as follow-up duration permitted ~~the~~ supportive criteria to be  
59  
60 applied. 15% of patients with a latest diagnosis of PD had initially had an alternative diagnosis.

1  
2  
3 Patients were excluded if they were not followed-up after baseline or if they had not received  
4  
5 dopaminergic treatment. ~~The study size was determined by the number of incident patients in the~~  
6  
7 ~~study period. Treatment was initiated and managed~~ Patients were treated according to the clinical  
8  
9 judgement of the treating clinicians.  
10  
11  
12  
13

#### 14 15 **Data collection and assessment of motor complications**

16  
17 At the baseline (i.e. diagnostic) assessment and at subsequent follow-up appointments, consenting  
18  
19 patients ~~who had consented~~ were interviewed and examined, and information gathered included  
20  
21 patient demographics and clinical characteristics (including the Unified PD Rating Scale [UPDRS]) and  
22  
23 details of parkinsonian medication. Data were also gathered on exposure to caffeine, alcohol and  
24  
25 smoking at verbal interview, including age at first exposure, average level of exposure before  
26  
27 baseline and, if relevant, year exposure stopped. At each annual assessment, patients were asked  
28  
29 about their ongoing exposures.  
30  
31  
32  
33  
34

35  
36 Data on motor complications were gathered from the prospectively acquired records of the  
37  
38 examining study physician and from part IV of the UPDRS. In patients who reported motor  
39  
40 complications, the month and year of onset were recorded from patient self-report or, in the case of  
41  
42 asymptomatic dyskinesias that were seen at the assessment, the date of that assessment ~~(which~~  
43  
44 ~~were based on clinical history and examination and included date of onset)~~ and from part IV of the  
45  
46 UPDRS. Dyskinesias did not have to be witnessed by a physician to be included, but if they were not  
47  
48 seen and the history was doubtful, they were not included. Severe motor complications were  
49  
50 defined as those which required changes to parkinsonian treatment after discussion with the  
51  
52 patient about their impact.  
53  
54  
55  
56  
57

#### 58 **Analysis**

59  
60

1  
2  
3 The data were extracted from the PINE database (26<sup>th</sup> June, 2013), checked and cleaned. ~~Medication~~  
4 ~~histories were updated each year, from which we calculated t~~The cumulative levodopa only dose  
5 and the total levodopa-equivalent dose (LED)<sup>25</sup> (including any dopamine replacement therapy) were  
6 calculated up to four years from diagnosis since almost all surviving patients had been followed-up  
7 for four years. Levodopa and levodopa-equivalent doses were calculated as levodopa or levodopa-  
8 equivalent dose in milligrams multiplied by number of days of treatment and divided by 10<sup>5</sup> to give  
9 units equivalent to about 70mg levodopa, on average, a day for 4 years. ~~Measures of cumulative~~  
10 ~~lifetime exposure at baseline for caffeine, alcohol and smoking were calculated. Cumulative A~~alcohol  
11 and caffeine lifetime exposure ~~was were~~ divided into tertiles and smoking exposure was categorised  
12 as never, low and high because there were large numbers of non-smokers in our cohort. ~~Weight of~~  
13 ~~caffeine was calculated on the basis of a c~~Cups of tea and coffee were assumed to containing 47mg  
14 and 62mg of caffeine respectively ~~and a cup of coffee containing 62mg.~~<sup>26</sup> ~~Measures Tertiles~~ of  
15 cumulative alcohol and caffeine exposure ~~to caffeine and alcohol~~ over three years after diagnosis  
16 were also calculated to investigate whether ongoing exposure after diagnosis was associated with  
17 fewer motor complications ~~and divided into tertiles; this was not calculated for smoking as there~~  
18 ~~were too few current smokers in the study.~~

19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42 We performed Kaplan-Meier survival analysis of motor fluctuation-free and dyskinesia-free survival  
43 from the start of any dopamine replacement therapy (levodopa, dopamine agonist, MAO-B inhibitor)  
44 with patients censored at death or last follow-up. Survival analyses were also performed with  
45 different time baselines to facilitate comparisons with previous studies: i) levodopa initiation; and ii)  
46 diagnosis. Cox proportional hazards modelling was performed to assess what factors independently  
47 influenced the development of motor complications ~~from the onset of dopaminergic therapy~~ (using  
48 start of dopaminergic treatment as the baseline for survival). Univariable (unadjusted) hazards ratios  
49 were firstly calculated for all the variables listed in table 1. There were too many variables to include  
50 all in a multivariable model. On the basis of *a priori* evidence we selected four variables to include  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

(irrespective of statistical significance) in the two main Cox regression models (i.e., one for the development of predicting motor fluctuations and one ~~for~~ dyskinesias): age at diagnosis, sex, motor UPDRS score at baseline and cumulative levodopa dose up to four years from diagnosis. This ensured ~~that there was~~ no fewer than n about 10 events per variable in the main models.<sup>27</sup> Additional exploratory analyses were performed to investigate the role of other variables including symptom duration prior to diagnosis, weight, MMSE score at diagnosis, different treatment measures ~~of levodopa exposure~~ (cumulative levodopa-equivalent dose, starting levodopa within one year of diagnosis) and measures of smoking, alcohol and caffeine exposure. These secondary analyses were performed by creating models with the four pre-specified variables together with each of the additional variables in turn. There were no missing data in the variables used in the main analysis; in the secondary analysis, if missing data were present for a particular variable, these observations were excluded from analyses including that variable. Statistical analyses were performed using SPSS version 21 and Stata version 12.

## RESULTS

~~241~~206 patients with a diagnosis of idiopathic PD at latest follow-up were identified from the PINE database (Figure 1), of which ~~11~~seven had declined clinical follow-up, ~~a further ten~~ had died before their first follow-up and ~~eightsix~~ had not received ~~any~~ dopaminergic medication by time of data extraction. These patients (mean age 70.8) were not treated because they had mild disease with tremor dominance (N=3), had early dementia while motor symptoms were still mild (N=1), refused treatment (N=1), or did not tolerate levodopa (N=1). The remaining 183 treated idiopathic PD patients (57.4% male, mean age at diagnosis 71.7 years) were included in the main analyses. The mean duration of follow-up was 59 months (SD 22). 66 patients (36.1%) died during the follow-up. Five patients (2.7%) were lost to clinical follow-up. 128 patients (69.9%) started levodopa within the first year of follow up (median duration to treatment onset 4 months, IQR 0-14 months). Most

1  
2  
3 patients (69.9%) received levodopa in the first year after diagnosis and a further 24 (13.1%) received  
4  
5 levodopa within four years of follow-up. The patients who received dopaminergic therapy in the first  
6  
7 four years, but not levodopa, were mostly treated with ropinirole (33 patients), pramipexole (17  
8  
9 patients), selegiline (13 patients), COMT inhibitors (2 patients), rasagiline (1 patient), or ergot-  
10  
11 derived dopamine agonists (2 patients).  
12  
13  
14

### 17 Motor Fluctuations

18  
19 Motor fluctuations occurred in 39 patients (21.3%) ~~by the time of data extraction~~ (see table 1 and  
20  
21 [figure 2A](#)). The majority of these were severe enough to require changes in therapy (25 patients  
22  
23 [13.7% of total participants, 64.1% of those with motor fluctuations]). These changes were mostly  
24  
25 increased frequency of levodopa dosage or adding a controlled release levodopa at night. [Kaplan-](#)  
26  
27 [Meier estimates of probability of developing motor fluctuations at five years, with different](#)  
28  
29 [baselines for time measurement, are shown in table 3. After five years on therapy the Kaplan-Meier](#)  
30  
31 [estimate of the probability of developing any motor fluctuations was 29.2% \(95% CI 21.5–38.8%\) and](#)  
32  
33 [of developing severe motor fluctuations was 19.8% \(95% CI 13.4–28.8%\) \(Figure 2A\). In the 160](#)  
34  
35 [patients treated with levodopa, probability of developing any motor fluctuation five years from](#)  
36  
37 [levodopa initiation was 30.6% \(95% CI 22.6–40.7%\). In 191 patients \(including eight untreated](#)  
38  
39 [patients\) the probability of developing motor fluctuations five years from diagnosis was 23.4% \(95%](#)  
40  
41 [CI 16.6–30.4%\).](#) The factors independently associated with the development of motor fluctuations in  
42  
43 the main multivariable model were higher cumulative levodopa dose ~~over the four follow-up years~~  
44  
45 ~~since baseline~~, female sex, and younger age at diagnosis (Table 1). In ~~the~~ secondary analyses the  
46  
47 presence of tremor at diagnosis was associated with a higher rate and moderate (though not high)  
48  
49 lifetime caffeine intake was associated with a lower rate of motor fluctuations. ~~None of the other~~  
50  
51 ~~variables was significantly associated in multivariable analyses.~~  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1.** Characteristics of patients who developed motor fluctuations

Characteristics	Patients with <b>MF</b> <u>fluctuations</u> N=39	Patients without <b>MF</b> <u>fluctuations</u> N=144	Unadjusted HR (95% CI)	Adjusted HR* <u>‡</u> (95% CI)
Age at diagnosis in years, median (IQR)	71 (64-74)	74 (69-80)	0.97 (0.94-0.99)	0.93 (0.90-0.97)
Sex: Female, N (%)	23 (59.0%)	55 (38.2%)	1.80 (0.95-3.40)	2.41 (1.19-4.89)
Weight at diagnosis in kg, median (IQR)	70 (64-84)	73 (62-83)	1.00 (0.98-1.03)	1.02 (0.99-1.05)
Motor UPDRS at diagnosis, median (IQR)	26 (18-36)	24 (15-32)	1.02 (0.99-1.05)	1.00 (0.96-1.03)
MMSE at diagnosis, median (IQR) (N=14 missing)	29 (28-30)	29 (27-29)	1.17 (0.97-1.42)	1.13 (0.90-1.42)
Tremor at diagnosis, N (%)	37 (95.0%)	123 (85.4%)	3.50 (0.84-14.58)	4.80 (1.12-20.72)
<u>Duration between symptom onset and diagnosis in years, median (IQR)</u>	<u>1.17 (0.83-2.00)</u>	<u>1.17 (0.75-2.06)</u>	<u>0.93 (0.75-1.14)</u>	<u>0.89 (0.71-1.13)</u>
Started on Levodopa within 1 year from diagnosis, N (%)	25 (64.1%)	103 (71.5%)	0.91 (0.47-1.76)	0.75 (0.29-1.92)
Cumulative Levodopa dose 4 years from diagnosis, median (IQR)	5.56 (1.40-7.60)	2.56 (0.63-4.38)	1.16 (1.04-1.30)	1.38 (1.19-1.60)
Cumulative LED* 4 years from diagnosis, median (IQR)	6.43 (3.37-7.60)	3.28 (1.88-5.08)	1.24 (1.08-1.46)	1.01 (0.76-1.36)
<u>PD Subtype, N (%)</u>				
<u>PIGD</u>	<u>17 (43.6%)</u>	<u>75 (52.1%)</u>	<u>1</u>	<u>1</u>
<u>Intermediate</u>	<u>6 (15.4%)</u>	<u>20 (13.9%)</u>	<u>1.33 (0.53-3.38)</u>	<u>2.00 (0.73-5.44)</u>
<u>Tremor dominant</u>	<u>16 (41.0%)</u>	<u>49 (34.0%)</u>	<u>1.31 (0.66-2.60)</u>	<u>1.59 (0.78-3.28)</u>
Smoking lifetime exposure, N (%)				
Pack years [cigarettes per day / 20 x number of years of exposure]				
Never	27 (69.2%)	78 (54.2%)	1	1
Low (1-18)	6 (15.4%)	37 (47.4%)	0.59 (0.24-1.43)	0.79 (0.32-1.94)
High (>18)	6 (15.4%)	29 (20.1%)	0.65 (0.27-1.57)	0.74 (0.30-1.85)
Current smokers at diagnosis, N (%)	4 (10.3%)	8 (5.5%)	1.70 (0.60-4.78)	1.40 (0.50-4.00)
Alcohol lifetime exposure, N (%)				
[units of alcohol per week x years of exposure]				
Never/Low(<40)	16 (41.0%)	45 (31.3%)	1	1
Moderate(40-240)	12 (30.8%)	49 (34.0%)	0.73 (0.35-1.56)	0.79 (0.35-1.77)
High(>240)	11 (28.2%)	50 (34.7%)	0.63 (0.29-1.36)	0.71 (0.30-1.70)
Alcohol 3 years after diagnosis, N (%)				
Never/Low(<1)	14 (35.9%)	58 (40.3%)	1	1
Moderate(1-11)	11 (28.2%)	38 (26.4%)	1.19 (0.54-2.62)	1.70 (0.73-3.97)
High(>11)	14 (35.9%)	48 (33.3%)	1.18 (0.56-2.47)	1.70 (0.79-3.60)
Caffeine lifetime exposure, N (%)				
[weight (in mg) per day x years of exposure]				
Never/Low(< 10,600)	17 (43.6%)	44 (30.6%)	1	1
Moderate (10,600 - 16,400)	13 (33.3%)	48 (33.3%)	0.53 (0.26-1.10)	0.34 (0.15-0.76)
High (>16,400)	9 (23.1%)	52 (36.1%)	0.50 (0.22-1.12)	0.57 (0.24-1.40)
Caffeine 3 years after diagnosis, N (%)				
Never/Low (<513)	8 (20.5%)	53 (36.8%)	1	1
Moderate(513-744)	18 (46.2%)	42 (29.2%)	1.59 (0.68-3.72)	1.58 (0.62-4.06)
High(>744)	13 (33.3%)	49 (34.0%)	1.10 (0.46-2.67)	1.12 (0.44-2.89)

\*Cumulative levodopa equivalent dose (LED) up to 4 years from diagnosis (mg Levodopa equivalent dose (mg) x number of days of treatment x 10<sup>-5</sup>; one unit is equivalent equals about to 70mg levodopa on average a day for 4 years). ‡Variables adjusted for the variables in the final multivariable model (age at diagnosis, sex, motor UPDRS at diagnosis, and cCumulative Levodopa dose 4 years from diagnosis). Abbreviations: HR=hazards ratio; IQR=interquartile range; PIGD= postural instability and gait disorder; MF= motor fluctuations.

## Dyskinesias

52 patients (28.4%) ~~had developed dyskinesias by the time of data extraction (see table 2 and figure 2B)~~. At onset, only three patients (1.6% of total participants, 5.8% of those with dyskinesia) rated their dyskinesias as painful and five (2.7% of total participants, 9.6% of those with dyskinesia) as mildly disabling; the rest were not disabling. Only 8 patients (4.4% of total participants, 15.4% of those with dyskinesia) developed dyskinesias which required treatment changes (such as decrease of levodopa dose or addition of amantadine). ~~The median dyskinesia-free survival time to onset of dyskinesias was 85 months. After five years on therapy the Kaplan-Meier estimates of the probability of developing dyskinesias after five years, with different baselines for time measurement, are shown in table 3. was 37.0% (95% CI 28.5–47.1%) and of developing severe dyskinesias was 4.0% (95% CI 1.5–10.4%) (Figure 2B). The median time to onset of dyskinesias was 85 months. In the 160 patients treated with levodopa, probability of developing any dyskinesia five years from levodopa initiation was 43.6% (95% CI 33.7–54.9). In 191 patients (including eight untreated patients) the probability of developing dyskinesias five years from diagnosis was 29.3% (95% CI 22.5–37.6%). Higher cumulative levodopa dose at 4 years from diagnosis and, female sex were found to be independent risk factors for the development of dyskinesias in the main multivariable model (Table 2). In the additional models, symptom duration and the presence of tremor at diagnosis was were associated with higher rates of more dyskinesias and there was a suggestion that higher MMSE score was associated with increased risk.~~

**Table 2.** Characteristics of patients who developed dyskinesias

Characteristics	Patients with dyskinesias N=52	Patients without dyskinesias N=131	Unadjusted HR (95% CI)	Adjusted HR** (95% CI)
Age at diagnosis in years, median (IQR)	73 (70-78)	73 (65-80)	1.02 (0.99-1.05)	1.00 (0.97-1.03)
Sex: Female, N (%)	29 (55.8%)	49 (37.4%)	1.79 (1.03-3.10)	2.51 (1.40-4.51)
Weight at diagnosis in Kg, median (IQR)	67 (60-75)	75 (64-85)	0.97 (0.96-0.99)	0.99 (0.96-1.01)

Motor UPDRS at diagnosis, median (IQR)	29 (19-37)	23 (15-32)	1.03 (1.01-1.06)	1.01 (0.98-1.04)
MMSE at diagnosis, median (IQR) (N=14 missing)	29 (28-29)	29 (27-29)	1.07 (0.94-1.23)	1.17 (1.00-1.36)
Tremor at diagnosis, N (%)	49 (94.2%)	111 (84.7%)	2.82 (0.88-9.07)	3.68 (1.14-11.90)
<u>Duration between symptom onset and diagnosis in years, median (IQR)</u>	<u>1.21 (0.71-2.15)</u>	<u>1.08 (0.75-2.00)</u>	<u>1.19 (1.05-1.35)</u>	<u>1.02 (1.01-1.03)</u>
Started on Levodopa within 1 year from diagnosis, N (%)	41 (78.8%)	87 (66.4%)	2.20 (1.13-4.30)	1.55 (0.65-3.70)
Cumulative Levodopa dose 4 years from diagnosis, median (IQR)	4.48 (2.34-6.90)	2.37 (0.23-4.07)	1.19 (1.08-1.32)	1.23 (1.08-1.40)
Cumulative LED <sup>‡</sup> 4 years from diagnosis, median (IQR)	5.87 (3.06-7.10)	3.28 (1.73-4.99)	1.19 (1.06-1.35)	1.00 (0.75-1.30)
<u>PD Subtype, N (%)</u>				
<u>PIGD</u>	<u>26 (50.0%)</u>	<u>66 (50.4%)</u>	<u>1</u>	<u>1</u>
<u>Intermediate</u>	<u>6 (11.5%)</u>	<u>20 (15.3%)</u>	<u>0.76 (0.31-1.85)</u>	<u>1.23 (0.50-3.10)</u>
<u>Tremor dominant</u>	<u>20 (38.5%)</u>	<u>45 (34.3%)</u>	<u>0.96 (0.54-1.73)</u>	<u>1.64 (0.86-3.12)</u>
Smoking lifetime exposure, N (%)				
Pack years [cigarettes per day / 20 x number of years of exposure]				
Never	30 (57.7%)	75 (57.3%)	1	1
Low (1-18)	10 (19.2%)	33 (25.2%)	0.95 (0.46-1.95)	1.08 (0.52-2.23)
High (>18)	12 (23.1%)	23 (17.6%)	1.40 (0.71-2.73)	1.21 (0.60-2.44)
Current smokers at diagnosis, N (%)	4 (8.0%)	8 (6.1%)	0.85 (0.30-2.37)	0.80 (0.30-2.30)
Alcohol lifetime exposure, N (%)				
[units of alcohol per week x years of exposure]				
Never/Low(<40)	22 (42.3%)	39 (29.8%)	1	1
Moderate(40-240)	14 (26.9%)	47 (35.9%)	0.53 (0.27-1.04)	0.63 (0.31-1.30)
High(>240)	16 (30.8%)	45 (34.4%)	0.66 (0.35-1.30)	0.80 (0.38-1.68)
Alcohol 3 years after diagnosis, N (%)				
Never/Low(<1)	21 (40.4%)	51 (38.9%)	1	1
Moderate(1-11)	11 (21.2%)	38 (29.0%)	0.67 (0.32-1.39)	0.90 (0.42-1.92)
High(>11)	20 (38.5%)	42 (32.1%)	1.09 (0.59-2.01)	1.63 (0.85-3.14)
Caffeine lifetime exposure, N (%)				
[weight (in mg) per day x years of exposure]				
Never/Low(< 10,600)	16 (30.7%)	45 (34.4%)	1	1
Moderate (10,600 - 16,400)	20 (38.5%)	41 (31.3%)	1.26 (0.65-2.43)	0.81 (0.40-1.64)
High (>16,400)	16 (30.7%)	45 (34.4%)	1.13 (0.56-2.25)	0.80 (0.38-1.67)
Caffeine 3 years after diagnosis, N (%)				
Never/Low (<513)	11 (21.2%)	50 (38.2%)	1	1
Moderate(513-744)	20 (38.5%)	40 (30.5%)	1.56 (0.74-3.29)	1.40 (0.64-3.08)
High(>744)	21 (40.4%)	41 (31.3%)	1.56 (0.75-3.24)	1.37 (0.65-2.87)

\*Cumulative levodopa equivalent dose (LED) up to 4 years from diagnosis (mg Levodopa equivalent dose x number of days of treatment x 10<sup>-5</sup>; one unit is equivalent to 70mg levodopa on average a day for 4 years).  
<sup>‡</sup>Variables are adjusted for the variables in the final multivariable model (age at diagnosis, sex, motor UPDRS at diagnosis, and cCumulative Levodopa dose 4 years from diagnosis). Abbreviations: PIGD= postural instability and gait disorder.

**Table 3: Kaplan-Meier probabilities of developing motor fluctuations and dyskinesias after five years from dopaminergic treatment initiation, from levodopa initiation, and from diagnosis.**

Baseline for time measurement	Motor fluctuations	Dyskinesias
Any complication		



<u>Starting dopaminergic treatment (N=183)</u>	<u>29.2% (21.5–38.8)</u>	<u>37.0% (28.5–47.1)</u>
<u>Starting levodopa treatment (N=160)</u>	<u>30.6% (22.6–40.7)</u>	<u>43.6% (33.7–54.9)</u>
<u>Diagnosis (N=189)</u>	<u>23.42.8% (16.67–30.47)</u>	<u>29.36% (22.57–37.68)</u>
<u>Severe complications</u>		
<u>19.8% (13.4–28.8)</u>		
<u>4.0% (1.5–10.4)</u>		
<u>Starting dopaminergic treatment (N=183)</u>	<u>19.8% (13.4–28.8)</u>	<u>4.0% (1.5–10.4)</u>

95% confidence intervals are in parentheses.

### Motor fluctuations and dyskinesias

23 patients (12.6%) ~~had~~ developed both fluctuations and dyskinesias ~~by the time of data extraction,~~ of whom 14 had developed dyskinesias first.

### DISCUSSION

~~We have estimated that a~~About 30% of patients with PD developed ~~ed~~ motor fluctuations and about 37% developed ~~ed~~ dyskinesias within five years of starting dopaminergic treatment. These were higher risks than described in two other community-based incidence cohorts that examined the development of dyskinesias. A ~~Mayo Clinic series from the Mayo Clinic, between 1976 and 1990~~ reported that ~~30% of patients developed~~ dyskinesias ~~of any severity were present in 30% of patients~~ by five years of starting levodopa<sup>8</sup> and in ~~an incident cohort in Cambridge, UK, another study-~~ fewer than 20% of patients developed dyskinesias five years from diagnosis.<sup>7</sup> The reasons for these differences, ~~between similar studies,~~ are unclear. No previous community-based inception studies have reported the frequency of motor fluctuations. We found complications to be less common than several other studies, some of which were older and therefore used higher levodopa doses than ~~are~~ ~~is~~ used in current practice.<sup>4,18</sup> Dyskinesias were more common in our cohort than motor fluctuations, similar to some studies<sup>15,28</sup> but not others.<sup>16,12,18</sup> Disabling dyskinesias were rare and, although ~~the majority of most~~ patients with motor fluctuations did ~~have need~~ changes in treatment, ~~due to their development, only a small minority~~ ~~very few (4%)~~ developed dyskinesias necessitating ~~treatment~~

1  
2  
3 changes ~~in treatment (4% at 5 years)~~. This is lower than one previous incident study in which  
4 ~~reported that~~ 17% of patients required treatment changes developed for dyskinesias ~~that required~~  
5 ~~treatment changes by within~~ five years of levodopa treatment with initiation levodopa.<sup>8</sup> That study  
6  
7  
8 used patient records between 1976 and 1990 and the ~~difference in lower~~ incidence of severe  
9  
10 dyskinesias in our study, could ~~also~~ be due to lower levodopa doses used in more recent prescribing  
11  
12  
13 practice.  
14  
15  
16  
17

18  
19 Levodopa exposure has consistently been reported as the strongest risk factor for the development  
20  
21 of motor fluctuations and dyskinesias in observational studies,<sup>4,8,16</sup> randomised trials of levodopa  
22  
23 versus dopamine agonists<sup>29,30</sup> and randomised trials of different levodopa doses.<sup>31</sup> Previous studies  
24  
25 have investigated several measures of levodopa exposure, including the initial average daily dose;<sup>7</sup>  
26  
27 average daily LED;<sup>8</sup> or levodopa dose at onset of dyskinesias (or ~~end of study end~~ in those without  
28  
29 dyskinesias).<sup>12</sup> Here we have compared cumulative both levodopa only and, levodopa-equivalent  
30  
31 doses up to four years and early (within one year of diagnosis) commencement of levodopa.  
32  
33 Although these variables were correlated, only cumulative levodopa dose was significantly  
34  
35 associated with motor complications when they were entered into a multivariable model together.  
36  
37 This suggests that there is little additional effect of non-levodopa dopaminergic treatments, ~~which is~~  
38  
39 similar to findings from a recent meta-analysis.<sup>32</sup> It also suggests there is no absolute requirement to  
40  
41 avoid early levodopa treatment in PD but, as others have suggested,<sup>12</sup> it is important to use the  
42  
43 smallest dose that adequately controls the patient's symptoms throughout the course of PD. The  
44  
45 fact that baseline motor severity (UPDRS) was not an independent risk factor for motor  
46  
47 complications suggests that the association between cumulative levodopa dose and motor  
48  
49 complications is not just due to worse disease severity with greater dopaminergic neuronal loss in  
50  
51 those needing more levodopa. ~~It can also be argued that levodopa dose is a proxy for disease~~  
52  
53 ~~severity, so that those with more aggressive disease are both more likely to get motor complications~~  
54  
55 ~~and to receive more levodopa. However, Our data showed that baseline motor was not an~~  
56  
57  
58  
59  
60

1  
2  
3 independent risk factor, although we may have been underpowered to detect this, which suggests  
4 ~~this finding is not confounded by disease severity. This is in~~ By contrast to ~~This conflicts with~~ one  
5  
6  
7 large trial which found that both baseline disease severity and levodopa doses were associated with  
8  
9  
10 higher frequency of motor complications.<sup>12</sup> However, e~~Evidence~~ that levodopa increases risk of  
11  
12 dyskinesias independently of disease severity also comes from randomised clinical trials, in which  
13  
14 disease severity is randomly allocated to each arm, and those with higher doses of levodopa<sup>31</sup> or  
15  
16 levodopa and entacapone<sup>33</sup> had higher incidence of dyskinesias.  
17  
18

19  
20  
21 Many previous studies have shown ~~a relationship between that~~ younger age at PD-onset ~~and~~  
22 ~~developing motor complications is associated with more, in particular~~ dyskinesias,<sup>9,10</sup> and it was the  
23  
24 most powerful predictor in a recent large trial.<sup>12</sup> We found that age at diagnosis ~~is an independent~~  
25  
26 ~~risk factor for developing motor fluctuations, but not~~ did not predict dyskinesias. ~~This latter, similar~~  
27  
28 ~~to finding supports results from~~ another community-based incidence study ~~that showed that age at~~  
29  
30 ~~baseline was not a risk factor for dyskinesias.~~<sup>7</sup> It may be that, as a community-based incidence study,  
31  
32 with proportionally few young-onset patients (4.4% under 50), there was insufficient power to  
33  
34 detect an effect of age on dyskinesias.  
35  
36  
37  
38  
39  
40  
41

42 Duration between symptom onset and diagnosis was found to be an independent risk factor for  
43 developing dyskinesias but not motor fluctuations. This result was independent of baseline disease  
44 severity and levodopa dose so does not appear to be an effect of those presenting later being  
45 treated with higher doses of levodopa. This finding must be interpreted cautiously because it was a  
46 secondary analysis and the variable is subject to recall bias but it may suggests that patients that  
47 with more indolent onset of their PD symptoms may be at a higher risk of developing dyskinesias.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

58 The presence of tremor at diagnosis was associated with higher risk of both motor fluctuations and  
59  
60 dyskinesias in the secondary analyses, which contrasts with a previous smaller study.<sup>34</sup> Although ~~this~~

1  
2  
3 ~~was~~ consistent for both types of complications, the number without any tremor at baseline ~~was~~  
4 ~~small and the~~ in this post-hoc analysis was ~~not pre-specified~~ small so this finding. ~~This result~~, whilst  
5  
6 novel and interesting, ~~needs to be~~ requires replication ~~in other studies~~.

7  
8  
9  
10  
11  
12 Female gender was an independent risk factor for both motor fluctuations and dyskinesias, as  
13 previous studies have also shown.<sup>12</sup> ~~The reasons for these gender differences in the development of~~  
14 motor complications are unclear. A possible explanation is that the lower average weight in females  
15 results in higher levodopa doses per body weight, and some previous studies found lower weight  
16 was a risk factor for dyskinesias.<sup>357,368</sup> We did not, however, demonstrate an association with  
17 baseline weight but changes in weight after diagnosis may be more important in the development of  
18 complications. It has also been suggested that females have a reduced genetic protection from a  
19 dopamine receptor polymorphism,<sup>11</sup> and hormonal differences may be important, with evidence  
20 from animal models of effects of oestrogen on the basal ganglia.<sup>3790</sup>

21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36 Moderate lifetime caffeine exposure was associated with a reduced risk of developing motor  
37 fluctuations in the secondary multivariable analyses but there was no dose-response gradient and,  
38 given the large number of associations tested in the secondary analyses, it may well be a false  
39 positive. Nevertheless, Observational data from a clinical trial showed caffeine was associated with a  
40 lowered risk of dyskinesias<sup>20</sup> and a ~~clinical~~ trial of another adenosine A2A antagonist, istradefylline  
41 reduced daily OFF time.<sup>21</sup> ~~Moderate lifetime caffeine exposure was associated with a reduced risk of~~  
42 ~~developing motor fluctuations in the secondary multivariable analyses but there was no dose-~~  
43 ~~response gradient and, given the large number of associations tested in the secondary analyses, it~~  
44 ~~may well be a false positive. Similarly, w~~We did not find ~~caffeine~~, smoking or alcohol exposure,  
45 either before or after diagnosis to be associated with lower risk of dyskinesias. This is ~~in~~  
46 ~~the~~ inconsistent with a previous study which showed smoking was not associated with motor  
47 complications.<sup>14</sup> However, we ~~did not have~~ lacked power to identify ~~a small effects~~ of these

1  
2  
3 exposures on motor complications; ~~data was collected retrospectively for pre diagnostic exposure;~~  
4  
5 ~~and there were very few current smokers in the cohort.~~  
6  
7

8  
9  
10 The principal strengths of this study are its prospective design; the representative sample (attempts  
11 were made ito identify all patients in the community with a new diagnosis of PDparkinsonian  
12 syndrome); ~~that diagnoses were~~ regularly reviewed of diagnoses to ~~achieve high~~ improve diagnostic  
13 accuracy; ~~that patients were reviewed clinically~~ frequent (at least yearly) clinical review to obtain  
14 data on motor complications; very high study retention; and careful statistical analyses. Additionally,  
15 cumulative levodopa doses were calculated up to 4 years rather than at complication onset. This is  
16 clearly better than comparing levodopa dose at onset of motor complications with levodopa dose at  
17 end of study in those without complications as this is confounded by difference in time.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29  
30  
31 The study has several limitations. Firstly, study size, while not small in terms of previous studies of  
32 ~~the development of~~ motor complications, is ~~not large enough~~ insufficient to identify weak  
33 associations or investigate interactions. Secondly, average follow-up duration was only about five  
34 years, so better data may be obtained with longer follow-up. Thirdly, ~~cumulative levodopa doses~~  
35 ~~were calculated up to 4 years and not at complication onset. However, identifying a time-point for~~  
36 ~~control comparisons would be difficult if this was done and th~~ This is clearly better than comparing  
37 levodopa dose at onset of motor complications with levodopa dose at end of study in those without  
38 complications as this is clearly confounded by difference in time. Fourthly, some inaccuracy in  
39 defining onset of complications is inevitable. Exact timing of onset of both dyskinesias and motor  
40 fluctuations was mostly subject to patient recall, although some patients' dyskinesias were observed  
41 at clinic visits before they were noticed by the patients themselves, and were recorded as starting  
42 when seen. Thus the time to onset of dyskinesias may be overestimated. Assessment of severity was  
43 based on data about changes in therapy, which was derived from comprehensive clinical letter that  
44 invariably included reasons for treatment changes so we believe this was a reliable assessment.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Fourthly, the secondary analyses must be considered as exploratory as many variables were included  
4 examined and ~~the associations identified may therefore be type I errors~~ are possible false positives.  
5  
6  
7

8 Fifthly, data on caffeine, smoking and alcohol were partly retrospective, only average exposures  
9  
10 were used, and we did not gather data on sources of caffeine other than tea and coffee.  
11  
12

13  
14  
15 In conclusion, we are the first to describe the development of both motor fluctuations and  
16  
17 dyskinesias in a representative, community-based, incident cohort of PD. We estimate that 29% and  
18  
19 37% develop motor fluctuations and dyskinesias respectively after 5 years of dopaminergic  
20  
21 treatment. Dyskinesias requiring treatment changes were rare (4% at 5 years), which is lower than  
22  
23 previous estimates. ~~Female sex, Higher cumulative levodopa dose,~~ female sex, and tremor at  
24  
25 diagnosis were independent risk factors for both motor complications; ~~and~~ moderate lifetime  
26  
27 caffeine exposure and younger age ~~with~~ for fewer motor fluctuations; ~~and longer pre-diagnosis~~  
28  
29 symptom duration for more dyskinesias. Further work with more patients with longer follow-up  
30  
31 would be useful ~~to obtain~~ for more detailed analysis of ~~the risk factors associated with development~~  
32  
33 of motor complications. Individual-patient-data meta-analysis of existing representative studies  
34  
35 would be an efficient way to do this.  
36  
37  
38  
39  
40  
41

## 42 **ACKNOWLEDGEMENTS**

43  
44  
45 We acknowledge funding for the PINE study from Parkinson's UK, the Scottish Chief Scientist Office,  
46  
47 the BMA Doris Hillier award, RS Macdonald Trust, the BUPA Foundation, NHS Grampian  
48  
49 endowments and SPRING. We thank the patients for their participation and the research staff who  
50  
51 collected data and supported the study database.  
52  
53  
54  
55  
56  
57

## 58 **AUTHOR'S ROLES**

1  
2  
3 The authors contributed to the following specific roles in the project and manuscript preparation as  
4 indicated:  
5

- 6  
7  
8 1. Research project: A. Conception, B. Organization, C. Execution;  
9  
10 2. Statistical Analysis: A. Design, B. Execution, C. Review and Critique;  
11  
12 3. Manuscript Preparation: A. Writing of the first draft, B. Review and Critique  
13

14 Nicholas W Scott (1B, 1C, 2B, 2C, 3A)

15  
16 Angus D Macleod (1B, 2A, 2B, 2C, 3B)

17  
18 Carl E Counsell (1A, 1B, 2C, 3B)  
19  
20  
21  
22  
23

#### 24 FINANCIAL DISCLOSURE

25  
26  
27  
28 Nicholas W Scott: none  
29

30  
31 Angus D Macleod: Funded by a Clinical Academic Fellowship from the Scottish Chief Scientist Office.  
32

33 Also received research funding from Parkinson's UK.  
34  
35  
36  
37

38 Carl E Counsell: Research funding from Parkinson's UK, Scottish Chief Scientist Office, National  
39  
40 Institute of Health Research, and Engineering and Physical Sciences Research Council  
41  
42  
43  
44  
45  
46  
47  
48  
49

#### 50 REFERENCES

- 51  
52  
53  
54 1. Samii A, Nutt JG, Ransom BR. Parkinson's disease. *Lancet* 2004; **363** (9423) :1783–1794.  
55  
56 2. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of  
57  
58 Parkinson's disease on the quality of life. *Movement Disorders* 2005; **20** (2): 224-230.  
59  
60

- 1  
2  
3 3. Marras C, Lang A, Krahn M, Tomlinson G, Naglie G. Parkinson Study Group, Quality of life in early  
4  
5 Parkinson's disease. *Movement Disorders* 2004; **19** (1): 22-28.  
6  
7
- 8 4. Ahlskog JE, Muentner MD. Frequency of levodopa-related dyskinesias and motor fluctuations as  
9  
10 estimated from the cumulative literature. *Movement Disorders* 2001; **16** (3): 448-458.  
11
- 12 5. Rybicki BA, Johnson CC, Gorell JM. Demographic differences in referral rates to neurologists of  
13  
14 patients with suspected Parkinson's disease: implications for case-control study design.  
15  
16 *Neuroepidemiology* 1995; **14** (2): 72–81.  
17
- 18 6. Fitzsimmons PR, Blayney S, Mina-Corkill S, Scott GO. Older participants are frequently excluded  
19  
20 from Parkinson's disease research. *Parkinsonism Related Disorders* 2012; **18** (5): 585–589.  
21
- 22 7. Evans JR, Mason SL, Williams-Gray CH, et al. The natural history of treated Parkinson's disease in  
23  
24 an incident, community based cohort. *J Neurology Neurosurgery Psychiatry* 2011; **82** (10): 1112-  
25  
26 1118.  
27
- 28 8. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk  
29  
30 among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. *Archives*  
31  
32 *Neurology* 2006; **63** (2): 205-209.  
33
- 34 9. Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of  
35  
36 Parkinson's disease onset. *Movement Disorders* 2005; **20** (3): 342–434.  
37
- 38 10. Ku S, Glass GA. Age of Parkinson's disease onset as a predictor for the development of  
39  
40 dyskinesia. *Movement Disorders* 2010; **25** (9): 1177–1182.  
41  
42
- 43 11. Zappia M, Annesi G, Nicoletti G, et al. Sex Differences in clinical and genetic determinants of  
44  
45 levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. *Archives Neurology*  
46  
47 2005; **62** (4): 601-605.  
48
- 49 12. Olanow CW, Kieburtz K, Rascol O, et al. Factors Predictive of the Development of Levodopa-  
50  
51 Induced Dyskinesia and Wearing-Off in Parkinson's Disease. *Movement Disorders* 2013; **28** (8):  
52  
53 1064-1071.  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
13. Rascol O, Brooks DJ, Korczyn AD, et al. Development of dyskinesias in a 5-year trial and ropinirole and L-dopa. *Movement Disorders* 2006; **21** (11): 1844–1850.
14. Hassin-Baer S, Molchadski I, Cohen OS, et al. Gender effect on time to levodopa-induced dyskinesias. *Journal of Neurology* 2011; **258** (11): 2048–2053.
15. Garcia-Ruiz PJ, del Val J, Fernandez IM, Herranz A. What factors influence motor complications in Parkinson disease?: A 10-year prospective study. *Clinical Neuropharmacology* 2012; **35** (1):1-5.
16. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study. *Brain* 2000; **123** (11): 2297–2305.
17. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. *Movement Disorders* 2005; **20** (Suppl. 11): S11-16.
18. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. *Archives Neurology* 2006; **63** (12): 1756–1760.
19. Noyce AJ, Bestwick JP, Silveira-Moriyama, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. *Annals Neurology* 2012; **72** (6): 893-901.
20. Wills AM, Eberly S, Tennis M, et al. Caffeine consumption and risk of dyskinesia in CALM-PD. *Movement Disorders* 2013; **28** (3): 380-383.
21. Mizuno Y, Kondo T, Japanese Istradefylline study group. Adenosine A2a receptor antagonist Istradefylline reduces daily OFF time in Parkinson's disease. *Movement Disorders* 2013; **28** (8): 1138-1141.
22. Taylor KS, Counsell CE, Harris CE, Gordon JC, Smith WC. Pilot study of the incidence and prognosis of degenerative Parkinsonian disorders in Aberdeen, United Kingdom: methods and preliminary results. *Movement Disorders* 2006; **21** (7): 976–982.
23. Caslake R, Scott N, Gordon J, et al. Age-, gender-, and socioeconomic status-specific incidence of Parkinson's disease and parkinsonism in North East Scotland: The PINE study. *Parkinsonism Related Disorders* 2013; **19** (5): 515-521.

- 1  
2  
3 | 24. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's  
4 | disease: a clinico-pathological study of 100 cases. *J Neurology Neurosurgery Psychiatry* 1992; **55**  
5 |  
6 | disease: a clinico-pathological study of 100 cases. *J Neurology Neurosurgery Psychiatry* 1992; **55**  
7 |  
8 | (3): 181-184.  
9 |
- 10 | 24-25. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa  
11 |  
12 | dose equivalency reporting in Parkinson's disease. *Movement Disorders* 2010; **25** (15): 2649-  
13 |  
14 | 2653.  
15 |
- 16 |  
17 | 25-26. U.S. Department of Agriculture, Agriculture Research Service. USDA National Nutrient  
18 |  
19 | Database for Standard Reference, Release 24. 2011.  
20 |
- 21 |  
22 | 26-27. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent  
23 |  
24 | variable in proportional hazards regression analysis, II: accuracy and precision of regression  
25 |  
26 | estimates. *Journal of Clinical Epidemiology* 1995; **48** (12): 1503-1510.  
27 |
- 28 |  
29 | 27-28. Mazzella L, Yahr MD, Marinelli L, Huang N, Moshier E, Di Rocco A. Dyskinesias predict the  
30 |  
31 | onset of motor response fluctuations in patients with Parkinson's disease on l-dopa  
32 |  
33 | monotherapy, *Parkinsonism Related Disorders* 2005; **11** (3): 151-155.  
34 |
- 35 |  
36 | 28-29. Parkinson study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease.  
37 |  
38 | A randomised controlled trial. *JAMA* 2000; **284** (15): 1931-1938.  
39 |
- 40 | 29-30. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating  
41 |  
42 | pramipexole vs levodopa in early Parkinson disease. *Archives Neurology* 2009; **66** (5): 563-570.  
43 |
- 44 |  
45 | 30-31. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. *New*  
46 |  
47 | *England Journal of Medicine* 2004; **351** (24): 2498-2508.  
48 |
- 49 | 31-32. Chondrogiorgi M, Tatsioni A, Reichmann H and Konitsiotis S. Dopamine agonist  
50 |  
51 | monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta-analysis of  
52 |  
53 | levodopa controlled trials. *European Journal of Neurology* 2014; **21** (3): 433-440.  
54 |
- 55 |  
56 | 32-33. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without  
57 |  
58 | entacapone in early Parkinson disease. The STRIDE-PD study. *Annals of Neurology* 2010; **68** (1):  
59 |  
60 | 18-27.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32
- 33-34. Kipfer S, Stephan MA, Schüpbach WM, Ballinari P, Kaelin-Lang A. Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia. *Archives Neurology* 2011; **68** (8): 1037-1039.
- 34-35. Sharma JC, Macnamara L, Hasoon M, Vassallo M, Ross IN. Cascade of levodopa dose and weight related dyskinesia in Parkinson's disease (LD-WD-PD cascade). *Parkinsonism Related Disorders* 2006; **12** (8): 499–505.
36. Sharma JC, Ross IN, Rascol O, Brooks D. Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. *European Journal of Neurology* 2008; **15** (5): 493–496.
- 35-37. Smith KM, Dahodwala, N. Sex differences in Parkinson's disease and other movement disorders. *Experimental Neurology* 2014; 259: 44-56.

### FIGURE LEGENDS


33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1. Flow chart of patients included in the analysis and initiation of levodopa treatment. FU: Follow-Up.

\*Patients received only dopamine agonist or MAO-B inhibitors within 4 years of follow-up, except for 5 patients who received treatment after 4 years of follow-up.

Figure 2. Kaplan-Meier estimates of the probability that PD patients on a dopaminergic therapy will be free from (A) motor fluctuations and (B) dyskinesias. -In each graph, the blue line represents the development of any motor complication and the red represents the development of severe complications, i.e., those necessitating needing changes to treatment.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



201x316mm (300 x 300 DPI)

1  
2  
3 Title: Motor complications in an incident Parkinson's disease cohort

4 Manuscript ID: EJoN-15-0093 Author(s): Scott, Nicholas; Macleod, Angus; Counsell, Carl

5  
6 We would like to thank the reviewers for their helpful comments and include a detailed reply to  
7 individual comments, in red, below.  
8

9 Reviewer: 1

10  
11 COMMENTS TO AUTHOR(S)

12  
13 The present investigation draws its major strength from its cohort based, incident-case methods.  
14 The theme is suitable for EJoN and of clinical relevance, as it addresses one of the major concerns  
15 when managing treatment options for Parkinson's Disease Patients. There are, however, one point that  
16 deserve better explanation. The authors should be more precise regarding the type of dopaminergic  
17 treatment other than levo-dopa. How many patients were on ropinirole, COMT inhibitors,  
18 pramipexole and so on.  
19

20 Response to Reviewer: 1

21  
22 We have inserted the following explanation into the text (page 7, lines 4-7):

23  
24 "The patients who received dopaminergic therapy in the first four years, but not levodopa, were  
25 mostly treated with ropinirole (33 patients), pramipexole (17 patients), selegiline (13 patients),  
26 COMT inhibitors (2 patients), rasagiline (1 patient), or ergot-derived dopamine agonists (2 patients)."  
27  
28

29  
30 Reviewer: 2

31  
32 COMMENTS TO AUTHOR(S)

- 33  
34 1. Did the authors collect information on the time between clinical onset of disease and  
35 diagnosis?  
36

37  
38 This information was collected but not analysed. In response to the reviewer's comment we have  
39 performed unadjusted and adjusted analysis of time between clinical onset and diagnosis. Longer  
40 duration between symptom onset and diagnosis was independently associated with risk of  
41 dyskinesias. The following changes have therefore been made:  
42

43  
44 Inserted into the Abstract (p. 2, lines 22-23): "longer symptom duration"

45  
46 Inserted into the Methods (p.6, lines 9-10): "symptom duration prior to diagnosis,"

47  
48 Inserted into Results Tables 1 (p.8) and 2 (p.9).

49  
50 Inserted into Discussion (p.12, lines 15-20): "Duration between symptom onset and diagnosis was  
51 found to be an independent risk factor for developing dyskinesias but not motor fluctuations. This  
52 result was independent of baseline disease severity and levodopa dose so does not appear to be an  
53 effect of those presenting later being treated with higher doses of levodopa. This finding must be  
54 interpreted cautiously because it was a secondary analysis and the variable is subject to recall bias  
55  
56  
57  
58  
59  
60

1  
2  
3 but it may suggest that patients with more indolent onset of their PD symptoms may be at a higher  
4  
5 risk of developing dyskinesias.”

6  
7 Inserted into Discussion (p.17, line 14): “and longer pre-diagnosis symptom duration for more  
8  
9 dyskinesias”

10  
11  
12  
13 2. What was the percentage of change of diagnosis from baseline over follow up in this cohort?

14  
15 We have inserted the following comment into text to add this information Methods (p.4 line 13-14):

16  
17 “15% of patients with a latest diagnosis of PD had initially had an alternative diagnosis.”

18  
19  
20  
21 3. How reliable was the assessment of severe motor complication; onset of dyskinesias and  
22 motor fluctuations?

23 We have added the following sentences into the Discussion (p.14 lines 7-13) to discuss the potential  
24 limitation of inaccuracies, particularly in identifying the timing of onset of these complications.

25  
26 “Thirdly, some inaccuracy in defining onset of complications is inevitable. Exact timing of onset of  
27 both dyskinesias and motor fluctuations was mostly subject to patient recall, although some  
28 patients’ dyskinesias were observed at clinic visits before they were noticed by the patients  
29 themselves, and were recorded as starting when seen. Thus the time to onset of dyskinesias may be  
30 overestimated. Assessment of severity was based on data about changes in therapy, which was  
31 derived from comprehensive clinical letter that invariably included reasons for treatment changes so  
32 we believe this was a reliable assessment.”

33  
34  
35  
36  
37 4. It would be interesting to know why eight patients did not start levo-dopa or any dopaminergic  
38 agent. Were they different from the others?

39  
40  
41 We have checked the case record for these patients and added the relevant data to the text. While  
42 doing this, we have discovered an error in the flow chart relating only to patients not included in the  
43 main analysis. We have updated figure 1 with the correct data. Those who were not treated were  
44 probably more likely to be tremor dominant in their presentation, but we have not made a formal  
45 comparison due to low numbers in this group. Their ages were similar. We have added the following  
46 reasons for patients not starting treatment into the Results section (p.6 , lines 22-25):

47  
48 “These patients (mean age 70.8) were not treated because they had mild disease with tremor  
49 dominance (N=3), had early dementia while motor symptoms were still mild (N=1), refused  
50 treatment (N=1), or did not tolerate levodopa (N=1).”

51  
52  
53  
54  
55  
56 5. What was the median duration of follow-up?  
57  
58  
59  
60

1  
2  
3 The median Follow-Up 60 months, IQR (48 months – 72 months). As this was very similar to the  
4 mean duration of follow-up (59 months, SD 22 months), which is stated in the text (page 7) we have  
5 not added the median follow-up to the manuscript.  
6  
7

8  
9 6. Did the authors distinguish in the analyses tremor dominant from akinetic phenotype with gait  
10 disturbances? This is of course different from presence of tremor at onset.  
11

12 We have added this data into the Results Tables 1 (p.8) and 2 (p.9). There was no significant effect of  
13 PD subtype on the risk of developing either motor fluctuations or dyskinesias.  
14  
15

16  
17 6. The authors should develop more the discussion on sex differences.  
18

19 We have expanded this section of the discussion, so that it now reads (p.13, lines 1-9):  
20

21 “Female gender was an independent risk factor for both motor fluctuations and dyskinesias, as  
22 previous studies have also shown.<sup>12</sup> The reasons for gender differences in the development of motor  
23 complications are unclear. A possible explanation is that lower average weight in females results in  
24 higher levodopa doses per body weight, and some previous studies found lower weight was a risk  
25 factor for dyskinesias.<sup>35,36</sup> We did not, however, demonstrate an association with baseline weight  
26 but changes in weight after diagnosis may be more important in the development of complications.  
27 It has also been suggested that females have a reduced genetic protection from a dopamine  
28 receptor polymorphism,<sup>11</sup> and hormonal differences may be important, with evidence from animal  
29 models of effects of oestrogen on the basal ganglia.<sup>37”</sup>  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1.** Characteristics of patients who developed motor fluctuations

Characteristics	Patients with fluctuations N=39	Patients without fluctuations N=144	Unadjusted HR (95% CI)	Adjusted HR* (95% CI)	
Age at diagnosis in years, median (IQR)	71 (64-74)	74 (69-80)	0.97 (0.94-0.99)	0.93 (0.90-0.97)	
Sex: Female, N (%)	23 (59.0%)	55 (38.2%)	1.80 (0.95-3.40)	2.41 (1.19-4.89)	
Weight at diagnosis in kg, median (IQR)	70 (64-84)	73 (62-83)	1.00 (0.98-1.03)	1.02 (0.99-1.05)	
Motor UPDRS at diagnosis, median (IQR)	26 (18-36)	24 (15-32)	1.02 (0.99-1.05)	1.00 (0.96-1.03)	
MMSE at diagnosis, median (IQR) (N=14 missing)	29 (28-30)	29 (27-29)	1.17 (0.97-1.42)	1.13 (0.90-1.42)	
Tremor at diagnosis, N (%)	37 (95.0%)	123 (85.4%)	3.50 (0.84-14.58)	4.80 (1.12-20.72)	
Duration between symptom onset and diagnosis in years, median (IQR)	1.17 (0.83–2.00)	1.17 (0.75-2.06)	0.93 (0.75-1.14)	0.89 (0.71-1.13)	
Started on Levodopa within 1 year from diagnosis, N (%)	25 (64.1%)	103 (71.5%)	0.91 (0.47-1.76)	0.75 (0.29-1.92)	
Cumulative Levodopa dose 4 years from diagnosis, median (IQR)	5.56 (1.40-7.60)	2.56 (0.63-4.38)	1.16 (1.04-1.30)	1.38 (1.19-1.60)	
Cumulative LED 4 years from diagnosis, median (IQR)	6.43 (3.37-7.60)	3.28 (1.88-5.08)	1.24 (1.08-1.46)	1.01 (0.76-1.36)	
PD Subtype, N (%)					
PIGD	17 (43.6%)	75 (52.1%)	1	1	
Intermediate	6 (15.4%)	20 (13.9%)	1.33 (0.53-3.38)	2.00 (0.73-5.44)	
Tremor dominant	16 (41.0%)	49 (34.0%)	1.31 (0.66-2.60)	1.59 (0.78-3.28)	
Smoking lifetime exposure, N (%)					
Pack years [cigarettes per day / 20 x number of years of exposure]	Never	27 (69.2%)	78 (54.2%)	1	1
	Low (1-18)	6 (15.4%)	37 (47.4%)	0.59 (0.24-1.43)	0.79 (0.32-1.94)
	High (>18)	6 (15.4%)	29 (20.1%)	0.65 (0.27-1.57)	0.74 (0.30-1.85)
Current smokers at diagnosis, N (%)	4 (10.3%)	8 (5.5%)	1.70 (0.60-4.78)	1.40 (0.50-4.00)	
Alcohol lifetime exposure, N (%)					
[units of alcohol per week x years of exposure]	Never/Low(<40)	16 (41.0%)	45 (31.3%)	1	1
	Moderate(40-240)	12 (30.8%)	49 (34.0%)	0.73 (0.35-1.56)	0.79 (0.35-1.77)
	High(>240)	11 (28.2%)	50 (34.7%)	0.63 (0.29-1.36)	0.71 (0.30-1.70)
Alcohol 3 years after diagnosis, N (%)					
	Never/Low(<1)	14 (35.9%)	58 (40.3%)	1	1
	Moderate(1-11)	11 (28.2%)	38 (26.4%)	1.19 (0.54-2.62)	1.70 (0.73-3.97)
	High(>11)	14 (35.9%)	48 (33.3%)	1.18 (0.56-2.47)	1.70 (0.79-3.60)
Caffeine lifetime exposure, N (%)					
[weight (in mg) per day x years of exposure]	Never/Low(< 10,600)	17 (43.6%)	44 (30.6%)	1	1
	Moderate (10,600 - 16,400)	13 (33.3%)	48 (33.3%)	0.53 (0.26-1.10)	0.34 (0.15-0.76)
	High (>16,400)	9 (23.1%)	52 (36.1%)	0.50 (0.22-1.12)	0.57 (0.24-1.40)
Caffeine 3 years after diagnosis, N (%)					
	Never/Low (<513)	8 (20.5%)	53 (36.8%)	1	1
	Moderate(513-744)	18 (46.2%)	42 (29.2%)	1.59 (0.68-3.72)	1.58 (0.62-4.06)
	High(>744)	13 (33.3%)	49 (34.0%)	1.10 (0.46-2.67)	1.12 (0.44-2.89)

\*Variables adjusted for the variables in the final multivariable model (age at diagnosis, sex, motor UPDRS at diagnosis, and cumulative levodopa dose 4). Abbreviation: PIGD= postural instability and gait disorder.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

**Table 2.** Characteristics of patients who developed dyskinesias

Characteristics	Patients with dyskinesias N=52	Patients without dyskinesias N=131	Unadjusted HR (95% CI)	Adjusted HR* (95% CI)
Age at diagnosis in years, median (IQR)	73 (70-78)	73 (65-80)	1.02 (0.99-1.05)	1.00 (0.97-1.03)
Sex: Female, N (%)	29 (55.8%)	49 (37.4%)	1.79 (1.03-3.10)	2.51 (1.40-4.51)
Weight at diagnosis in Kg, median (IQR)	67 (60-75)	75 (64-85)	0.97 (0.96-0.99)	0.99 (0.96-1.01)
Motor UPDRS at diagnosis, median (IQR)	29 (19-37)	23 (15-32)	1.03 (1.01-1.06)	1.01 (0.98-1.04)
MMSE at diagnosis, median (IQR) (N=14 missing)	29 (28-29)	29 (27-29)	1.07 (0.94-1.23)	1.17 (1.00-1.36)
Tremor at diagnosis, N (%)	49 (94.2%)	111 (84.7%)	2.82 (0.88-9.07)	3.68 (1.14-11.90)
Duration between symptom onset and diagnosis in years, median (IQR)	1.21 (0.71-2.15)	1.08 (0.75-2.00)	1.19 (1.05-1.35)	1.02 (1.01-1.03)
Started on Levodopa within 1 year from diagnosis, N (%)	41 (78.8%)	87 (66.4%)	2.20 (1.13-4.30)	1.55 (0.65-3.70)
Cumulative Levodopa dose 4 years from diagnosis, median (IQR)	4.48 (2.34-6.90)	2.37 (0.23-4.07)	1.19 (1.08-1.32)	1.23 (1.08-1.40)
Cumulative LED 4 years from diagnosis, median (IQR)	5.87 (3.06-7.10)	3.28 (1.73-4.99)	1.19 (1.06-1.35)	1.00 (0.75-1.30)
PD Subtype, N (%)				
PIGD	26 (50.0%)	66 (50.4%)	1	1
Intermediate	6 (11.5%)	20 (15.3%)	0.76 (0.31-1.85)	1.23 (0.50-3.10)
Tremor dominant	20 (38.5%)	45 (34.3%)	0.96 (0.54-1.73)	1.64 (0.86-3.12)
Smoking lifetime exposure, N (%)				
Pack years [cigarettes per day / 20 x number of years of exposure]				
Never	30 (57.7%)	75 (57.3%)	1	1
Low (1-18)	10 (19.2%)	33 (25.2%)	0.95 (0.46-1.95)	1.08 (0.52-2.23)
High (>18)	12 (23.1%)	23 (17.6%)	1.40 (0.71-2.73)	1.21 (0.60-2.44)
Current smokers at diagnosis, N (%)	4 (8.0%)	8 (6.1%)	0.85 (0.30-2.37)	0.80 (0.30-2.30)
Alcohol lifetime exposure, N (%)				
[units of alcohol per week x years of exposure]				
Never/Low(<40)	22 (42.3%)	39 (29.8%)	1	1
Moderate(40-240)	14 (26.9%)	47 (35.9%)	0.53 (0.27-1.04)	0.63 (0.31-1.30)
High(>240)	16 (30.8%)	45 (34.4%)	0.66 (0.35-1.30)	0.80 (0.38-1.68)
Alcohol 3 years after diagnosis, N (%)				
Never/Low(<1)	21 (40.4%)	51 (38.9%)	1	1
Moderate(1-11)	11 (21.2%)	38 (29.0%)	0.67 (0.32-1.39)	0.90 (0.42-1.92)
High(>11)	20 (38.5%)	42 (32.1%)	1.09 (0.59-2.01)	1.63 (0.85-3.14)
Caffeine lifetime exposure, N (%)				
[weight (in mg) per day x years of exposure]				
Never/Low(< 10,600)	16 (30.7%)	45 (34.4%)	1	1
Moderate (10,600 - 16,400)	20 (38.5%)	41 (31.3%)	1.26 (0.65-2.43)	0.81 (0.40-1.64)
High (>16,400)	16 (30.7%)	45 (34.4%)	1.13 (0.56-2.25)	0.80 (0.38-1.67)
Caffeine 3 years after diagnosis, N (%)				
Never/Low (<513)	11 (21.2%)	50 (38.2%)	1	1
Moderate(513-744)	20 (38.5%)	40 (30.5%)	1.56 (0.74-3.29)	1.40 (0.64-3.08)
High(>744)	21 (40.4%)	41 (31.3%)	1.56 (0.75-3.24)	1.37 (0.65-2.87)

\*Variables are adjusted for the variables in the final multivariable model (age at diagnosis, sex, motor UPDRS at diagnosis, and cumulative levodopa dose). Abbreviation: PIGD= postural instability and gait disorder.

**Table 3:** Kaplan-Meier probabilities of developing motor fluctuations and dyskinesias after five years from dopaminergic treatment initiation, from levodopa initiation, and from diagnosis.

Baseline for time measurement	Motor fluctuations	Dyskinesias
Any complication		
Starting dopaminergic treatment (N=183)	29.2% (21.5–38.8)	37.0% (28.5–47.1)
Starting levodopa treatment (N=160)	30.6% (22.6–40.7)	43.6% (33.7–54.9)
Diagnosis (N=189)	22.8% (16.7–30.7)	29.6% (22.7–37.8)
Severe complications		
Starting dopaminergic treatment (N=183)	19.8% (13.4–28.8)	4.0% (1.5–10.4)

95% confidence intervals are in parentheses.

For Peer Review

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





Figure 2  
203x295mm (300 x 300 DPI)

### Author Guarantee Statement

Kindly confirm that your manuscript meets the following criteria by marking an 'x' in each appropriate box on the left. Alternatively, print the form, fill it in and scan it for submission with your manuscript files.

X	<p>The manuscript is not, either in part or whole, under active consideration by any other journal, will not be submitted for review to another journal until European Journal of Neurology makes an editorial decision on it, and has not been published in any other journal in either hard-copy or electronic format.</p> <p><b>Note:</b> Abstracts and press reports published in connection with scientific meetings are not considered as publications.</p>
X	<p>All co-authors have made a substantial contribution to the design, data collection and analysis of the research and the drafting of the manuscript and have reviewed and accepted the contents of the manuscript prior to its submission.</p>
X	<p>There has been no ghost writing by anyone not named as a co-author. The manuscript is free from falsification, fabrication and plagiarism.</p>
X	<p>If the study involved people, human tissues, medical records or death certificates even retrospectively, the Methods/Patients section includes the full name of the institutional review board or ethics committee that approved the research protocol.</p> <p><b>Note:</b> If no such approval was needed according to the local regulations, that is explained in the Methods section.</p>
X	<p>If the study involved a specific intervention purely for research – even a questionnaire – the Methods/Patients section indicates that the study subjects or their next-of-kin gave informed consent for their participation.</p>
X	<p>Completed ICMJE disclosure forms for all authors are submitted along with the manuscript files. The manuscript includes a section titled 'Disclosure of conflict of interest'. This section details any financial relationships that the authors may have with the company whose drug or other product is described in the manuscript. Where no such relationship exists, the section indicates 'None'.</p>
X	<p>If the research being reported has received funding or other outside support, the manuscript includes a section titled 'Acknowledgements'. This section details the sources of funding and acknowledges the outside support.</p>
X	<p>If the manuscript reports the results of a randomized clinical trial, the details of trial registration are given in a section titled 'Trial registration'.</p>
	<p>Optional comments:</p>
	<p>Name/signature of the guarantor:          NICHOLAS Scott </p>